Substituted biphenyl compounds as CBL-b inhibitors
Substituted biphenyl compounds serve as effective CBL-B inhibitors, addressing the lack of specific treatments for CBL-B mediated diseases by enhancing immune responses and targeting cancer cells, offering a promising therapeutic approach for autoimmune, inflammatory, and cancer-related conditions.
Patent Information
- Application Number
- PCT/IB2024/054478
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-08
- Filing Date
- 2024-05-08
- Publication Date
- 2024-11-14
AI Technical Summary
Current treatments for diseases and disorders associated with CBL-B inhibition, such as autoimmune diseases, inflammatory diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, and asthma, lack effective CBL-B specific inhibitors, necessitating the development of novel therapeutic compounds.
Development of substituted biphenyl compounds that act as selective small-molecule inhibitors of CBL-B, capable of modulating immune responses and targeting cancer cells, thereby treating or preventing diseases mediated by CBL-b.
The compounds demonstrate high efficacy as CBL-B inhibitors with IC50 values of less than 500 nM, effectively inhibiting CBL-b activity, which can enhance immune cell activation and durability, offering potential therapeutic benefits for various diseases.
Smart Images

Figure IB2024054478_14112024_PF_FP_ABST
Abstract
Description
[0001] SUBSTITUTED BIPHENYL COMPOUNDS AS CBL-B INHIBITORS RELATED APPLICATIONS This application claims the benefit of Indian Provisional Application No. 202321032423 filed on May 08, 2023; which is hereby incorporated by reference in its entirety. TECHNICAL FIELD The present patent application is directed to substituted biphenyl compounds which are useful as CBL-B inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and / or disorders mediated by CBL-b. BACKGROUND OF INVENTION CBL (Casitas B-lineage Lymphoma) is a mammalian gene encoding the protein CBL which is an E3 ubiquitin-protein ligase. Cbl proteins are part of a family of ubiquitin ligases involved in cell signaling, protein ubiquitination, and degradation of protein substrates. The Cbl proteins are a highly conserved family of proteins with three isoforms c-Cbl (also termed Cbl2, Cbl-SL, or RNF55), Cbl-b (also termed RNF56) and Cbl-3 (also called Cbl-3) [Keane et al., Oncogene, 18: 3365–3375, 1999; Keane et al., Oncogene, 10: 2367–2377, 1995; Kim et al., Gene, 239: 145–154, 1999]. All three mammalian Cbl proteins are RING-type E3 ligases containing an N-terminal tyrosine kinase binding (TKB) domain consisting of a four-helical bundle, a calcium binding EF-hand and a Src homology (SH2) domain, followed by a linker helical region and the RING domain, responsible for their catalytic function. Cbl-b ubiquitinates all three TAM family members, Tyro-3, Axl, and Mer, which is responsible for immunosuppressive and metastatic action. The unique feature of the TKB domain is that it recognizes specific substrates of Cbl- b, which is achieved by binding to proteins containing specific phosphorylated tyrosine- containing motifs, such as Syk and Zap-70, and a range of receptor tyrosine kinases. The interaction of proteins with the TKB domain of Cbl is mediated by 3 distinct subdomains consisting of a 4-helix bundle (4H), a calcium-binding EF hand, and a variant SH2 domain, all 3 of which are functionally required to form a unique PTB (phosphotyrosine-binding) module [Meng et al., Nature, 398(6722): 84-90, 1999]. SH2 domain within the TKB recognizes tyrosine-phosphorylated proteins for ubiquitin conjugation [Mohapatra et al., Biochim Biophys Acta., 1833(1): 122-39, 2013]. A highly conserved α-helix of the L domain plays an important role in maintaining E3 activity [Zeng et al., Cell, 102(4): 533-9, 2000; Kassenbrock et al., J Biol Chem., 279(27): 28017-27, 2004]. The crystal structure shows that the L region contacts the TKB, RF, and E2 ubiquitin-conjugating enzymes. The RF domain has intrinsic E3 ubiquitin ligase activity and binds to ubiquitin-E2 for the transfer of ubiquitin to specific substrates [Budhidarmo et al., Trends Biochem Sci., 37(2): 58-65, 2012; Paolino et al., J Immunol., 186(4): 2138-47, 2011]. Recent studies indicates that the phosphorylation of Y363, located in the L region between TKB and RF domains, regulates the E3 activity of Cbl-b by 2 mechanisms: one is to remove the masking of the RF domain from the TKB domain, and the other is to form a surface to enhance binding affinity to E2s [Ryan et al., J Biol Chem., 285(31): 23687-98, 2010;]. Casitas B-lineage lymphoma proto-oncogene-b, a RING finger E3 ubiquitin-protein ligase, has been demonstrated to play a crucial role in establishing the threshold for T-cell activation and controlling peripheral T-cell tolerance via multiple mechanisms. In T cells, Cbl- b is predominantly expressed in peripheral T cells, whereas c-Cbl is mainly expressed in thymus, suggesting a distinct role of c-Cbl and Cbl-b in T-cell development and tolerance induction [Liu et al., Trends Immunol., 23(3): 140-3, 2002]. The E3 ubiquitin ligase cbl-b has been identified as a key intracellular checkpoint limiting T and NK cell activation. The blockade of cbl-b function by genetic deletion strongly enhances anti-tumor immune responses Cbl-b is expressed in all leukocyte subsets and regulates several signaling pathways in T cells, NK cells, B cells, and different types of myeloid cells. Cbl-b is thought to function largely by regulating T cell activity through degradation of phospho-inositol-3-kinase (PI-3-K) downstream of the CD28 costimulatory receptor. The role of Cbl-b in the negative regulation of T cell activation and tolerance induction are tightly controlled processes regulating immune responses to pathogens and tumors while preventing autoimmunity. Autoimmunity is mainly averted through central tolerance by negative selection of thymocytes carrying TCR for self- antigens. Cbl proteins not only regulate adaptive immune cell functions but are also critically involved in the regulation of innate lymphocyte populations, such as NK cells. NK cells are among the first cells to arrive at the inflamed tissue where they exert potent cytotoxic effector functions and modulate the local immune response [Paolino et al., Nature, 507(7493): 508–12, 2014]. NK cells are an attractive tool for cell-based immunotherapy because of their innate ability to discriminate between healthy and virally infected or naturally transformed cells. NK cell therapies include adoptive autologous or allogeneic cell therapy, wherein NK cells are used to support hematopoietic stem cell transplants. Adoptive Cell Therapy (ACT) is used in otherwise treatment-resistant cancers, including metastatic melanomas, gliomas, and renal carcinomas. In ACT, NK cells or T cells from a patient's own blood or tumor tissue are harvested, then grown into large numbers in the laboratory, and then the expanded cells are transferred back to the patient to enhance the patient’s immune system response to the cancer. In some versions of ACT, the T cells or NK cells are modified using genetic engineering to enable them to target the patient's cancer cells and kill the cancer cells more efficiently. Types of adoptive cell therapy include natural killer (NK) cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, engineered T-cell receptor therapy (TCR), and chimeric antigen receptor T-cell (CAR T) therapy. NK cell therapy uses NK cells, part of the innate immune system, and the first line of defense against infections and diseases, including cancer cells. As genetic ablation of cbl-b is associated with spontaneous development of autoimmunity and increased susceptibility to experimental induction of autoimmune diseases [Bachmaier et al., Nature, 403(6766): 211–6, 2000] and it is not surprising that several groups later found links between genetic cbl-b variants and susceptibility to autoimmunity in an animal model for diabetes [Yokoi et al., Nat Genet., 31(4): 391–4, 2002] as well as in various human autoimmune diseases such as type 1 diabetes [Bergholdt et al., J Leukoc Biol., 77(4): 579–85, 2005], lupus erythematodes [Padilla et al., Lupus, 20(6): 628–35, 2011], asthma [Dewan et al., BMC Med Genet., 13: 95, 2012], and multiple sclerosis [Sawcer et al., Nature, 476(7359): 214–9, 2011]. Adoptive Cell Therapy (ACT) is used in otherwise treatment-resistant cancers, including metastatic melanomas, gliomas, and renal carcinomas. In ACT, NK cells or T cells from a patient's own blood or tumor tissue are harvested, then grown into large numbers in the laboratory, and then the expanded cells are transferred back to the patient to enhance the patient’s immune system response to the cancer. In some versions of ACT, the T cells or NK cells are modified using genetic engineering to enable them to target the patient's cancer cells and kill the cancer cells more efficiently. Types of adoptive cell therapy include natural killer (NK) cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, engineered T-cell receptor therapy (TCR), and chimeric antigen receptor T-cell (CAR T) therapy. Cbl inhibitors include small molecules, peptides, nucleic acids, or antibodies that inhibit the Cbl enzymes. Cbl enzymes include c-Cbl, Cbl-b, and Cbl-c. Cbl inhibitors for use in methods of treatment and compositions of the disclosure, include, but are not limited to, compounds and pharmaceutical compositions for cell-based immunotherapy. The Cbl inhibitors can be used in in-vivo treatment methods to modulate the immune system, such as increasing activation of T cells, NK cells, circulating T cells, tumor infiltrating lymphocytes and B cells, to increase engraftment of infused ex vivo expanded immune cells, or to increase the durability of response to the infused ex vivo expanded immune cells. In addition, the Cbl inhibitors can be used to help expand such immune cells in vitro or ex vivo to increase their growth and proliferation or to modulate the phenotype of the resulting expanded immune cells. Several patent applications were published relating to compounds, which are useful as CBL inhibitors. PCT publication numbers WO / 2021 / 061853; WO / 2021 / 061870; WO / 2021 / 021761; WO / 2020 / 264398; WO / 2020 / 236654; WO / 2020 / 210508; WO / 2019 / 148005 discloses compounds as CBL inhibitors in the treatment of T cell dysfunction and cancer. Currently, due to the lack of CBL-B specific inhibitors, there is a largely unmet need for an effective way of treating disease and disorders associated with CBL-B inhibition includes but not limited to autoimmune diseases, inflammatory diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies and asthma. The improved therapeutic compounds, compositions and methods for the treatment for these disease and disorders are urgently required. CBL-B inhibition is an especially attractive target for cancer immunotherapy. The present disclosure provides novel, highly effective and selective small-molecule inhibitors of CBL-B. SUMMARY OF THE INVENTION In one aspect, the present invention relates to compound of formula (I) or stereoisomer or a wherein, ring ring B is selected from divalent phenyl or divalent 5- to 6-membered heteroaryl; at each occurrence ‘X’ is C or N; at each occurrence ‘Y’ is C or N; ‘----’ represents optional bond; at each occurrence, R1is selected from C1-8alkyl; at each occurrence, R2is independently selected from cyano, halogen, and C1-8alkyl; at each occurrence, R3is independently selected from cyano, halogen, C1-8alkyl, haloC-1-8alkyl, hydroxylC1-8alkyl, C1-8alkoxy, -COOH, -NRxRy, 4-6 membered heterocyclyl and C3-12cycloalkyl; wherein 4-6 membered heterocyclyl and C3-8cycloalkyl are unsubstituted or substituted with one or more substituents selected from halogen, cyano, cyanoC1-8alkyl, hydroxyl and hydroxylC1-8alkyl; alternatively, any two R3attached to the adjacent C or N atom combine together to form 5- to 6-membered fused heteroaryl ring which is unsubstituted or substituted by one or more R3a; R3ais independently selected from hydrogen and C1-8alkyl; Rxand Ryare independently selected from hydrogen, C1-8alkyl, haloC1-8alkyl, hydroxylC1-8alkyl, cyanoC1-8alkyl, -COO-C1-8alkyl, S(O)2C1-8alkyl, C3-12cycloalkyl, 4- 6 membered heterocyclyl and C3-8cycloalkylC1-8alkyl; wherein C3-12cycloalkyl, 4-6 membered heterocyclyl and C3-8cycloalkylC1-8alkyl are unsubstituted or substituted with one or more substituents selected from halogen, cyano, cyanoC1-8alkyl, hydroxyl and hydroxylC1-8alkyl; R4is selected hydrogen; R5ais independently selected from C1-8alkyl, haloC1-8alkyl, C3-12cycloalkyl and C3- 8cycloalkylC1-8alkyl; at each occurrence, R5bis independently selected from –CH(R6)-NR7R8; R6is selected from hydrogen; R7is selected from hydrogen; R8is selected from C1-8alkyl, C3-12cycloalkyl and C3-8cycloalkylC1-8alkyl; R7and R8joined together with the nitrogen atom to which they are attached, form a 3- 15 membered heterocyclyl; wherein 3-15 membered heterocyclyl is unsubstituted or substituted with one or more substituents selected from halogen and C1-8alkyl; ‘r’ is 0 or 1; ‘t’ is 0, 1 or 2; ‘m’ is 0, 1, 2 or 3; and ‘n’ is 1 or 2; In another aspect, the present invention relates to compound of formula (IA) or stereoisomer or a wherein, ring A is selected from , and ; ring B is selected from divalent phenyl or divalent 5- to 6-membered heteroaryl; X1and X2are independently represents C, N or S; ‘----’ between X1and X2represents optional bond; at each occurrence, R1is selected from halogen, C1-8alkyl, C1-8alkoxy, C1-8alkoxy-C1-8alkyl, cyano, hydroxyl, haloC1-8alkyl and hydroxylC1-8alkyl; at each occurrence, R2is independently selected from halogen, haloC1-8alkyl, cyano, - COOH, -COO-C1-8alkyl, C1-8alkyl, C1-8alkoxy, C1-8alkoxy-C1-8alkyl, 4-6 membered heterocyclyl and C3-12cycloalkyl; wherein the said 4-6 membered heterocyclyl and C3-8cycloalkyl are substituted with one or more substituents selected from halogen, cyano, hydroxyl, C1-8alkyl, haloC1-8alkyl, hydroxylC1-8alkyl, C1-8alkoxy and C1-8alkoxy-C1-8alkyl; at each occurrence, R3is independently selected from cyano, halogen, C1-8alkyl, haloC- 1-8alkyl, hydroxyl, hydroxylC1-8alkyl, C1-8alkoxy, C1-8alkoxy-C1-8alkyl, -COOH, -COO-C1- 8alkyl, -NRxRy, C6-10aryl, 4-6 membered heterocyclyl and C3-12cycloalkyl; wherein the said C6-10aryl, 4-6 membered heterocyclyl and C3-8cycloalkyl are unsubstituted or substituted with one or more substituents selected from halogen, cyano, hydroxyl, C1-8alkyl, cyanoC1-8alkyl, haloC1-8alkyl, C1-8alkoxy, C1-8alkoxy-C1-8alkyl and hydroxylC1-8alkyl; alternatively, any two R3groups attached to the adjacent C or N atom combine together to form 5- to 6-membered fused heteroaryl ring which is unsubstituted or substituted by one or more R3a; R3ais independently selected from halogen, cyano, hydroxyl, C1-8alkyl, haloC1-8alkyl, hydroxylC1-8alkyl, C1-8alkoxy and C1-8alkoxy-C1-8alkyl; Rxand Ryare independently selected from hydrogen, C1-8alkyl, haloC1-8alkyl, hydroxylC1-8alkyl, cyanoC1-8alkyl, -COO-C1-8alkyl, S(O)2C1-8alkyl, C3-12cycloalkyl, 4-6 membered heterocyclyl and C3-8cycloalkylC1-8alkyl; wherein the said C3-12cycloalkyl, 4-6 membered heterocyclyl and C3-8cycloalkylC1-8alkyl are unsubstituted or substituted with one or more substituents selected from halogen, cyano, C1-8alkyl, haloC1-8alkyl, cyanoC1-8alkyl, hydroxyl and hydroxylC1-8alkyl; R5ais independently selected from halogen, C1-8alkyl, haloC1-8alkyl, C3-12cycloalkyl and C3-8cycloalkylC1-8alkyl; at each occurrence, R5bis independently selected from –CH(R6)-NR7R8; R6is selected from hydrogen; R7is selected from hydrogen; R8is selected from C1-8alkyl, C3-12cycloalkyl and C3-8cycloalkylC1-8alkyl; R7and R8joined together with the nitrogen atom to which they are attached, form a 3- 15 membered heterocyclyl; wherein 3-15 membered heterocyclyl is unsubstituted or substituted with one or more substituents selected from halogen and C1-8alkyl; ‘r’ is 0 or 1; ‘t’ is 0, 1 or 2; ‘m’ is 0, 1, 2 or 3; and ‘n’ is 1 or 2; In yet another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable excipient. In yet another aspect, the present invention provides a method of treating or preventing from a disease, disorder, or condition mediated by CBL-b in a subject comprising administering the subject in need thereof an effective amount of a compound of the present invention. DETAILED DESCRIPTION OF THE INVENTION The compound of formula (I) as described herein involve one or more embodiments. Embodiments of formula (I) include compound of formula (IA), (IB), (IC) and (ID) as described hereinafter. It is to be understood that the embodiments below are illustrative of the present invention and are not intended to limit the claims to the specific embodiments exemplified. It is also to be understood that the embodiments defined herein may be used independently or in conjunction with any definition, any other embodiment defined herein. Thus the invention contemplates all possible combinations and permutations of the various independently described embodiments. For example, the invention provides compound of formula (I) as defined above wherein R1methyl (according to one embodiment defined below) and ‘r’ is 1 (according to another embodiment defined below). According to one embodiment, specifically provided are compound of formula (I), in which ring specifically provided are compound of formula (I), in which ring embodiment, specifically provided are compound of formula (I), in which ring embodiment, specifically provided are compound of formula (I), in which ring embodiment, specifically provided are compound of formula (I), in which R1is C1-8alkyl (e.g. methyl). According to yet another embodiment, specifically provided are compound of formula (I), in which R1is methyl. According to yet another embodiment, specifically provided are compound of formula (I), in which ‘r’ is 1. According to yet another embodiment, specifically provided are compound of formula (I), in which R1is methyl and ‘r’ is 1. According to yet another embodiment, specifically provided are compound of formula (I), in which ring B is divalent phenyl divalent 5- to 6-membered heteroaryl to yet another embodiment, specifically provided are compound of formula (I), in which ring specifically provided are compound of formula (I), in which ring specifically provided are compound of formula (I), in which ring embodiment, specifically provided are compound of formula (I), in which R2is cyano, halogen (e.g. chloro or fluoro) or C1-8alkyl (e.g. methyl). According to yet another embodiment, specifically provided are compound of formula (I), in which R2is cyano, chloro, fluoro or methyl. According to yet another embodiment, specifically provided are compound of formula (I), in which ‘t’ is 0, 1 or 2. According to yet another embodiment, specifically provided are compound of formula (I), in which ‘X’ is C or N. According to yet another embodiment, specifically provided are compound of formula (I), in which ‘X’ is C. According to yet another embodiment, specifically provided are compound of formula (I), in which ‘X’ is N. According to yet another embodiment, specifically provided are compound of formula (I), in which R3is halogen (e.g. chloro or fluoro) or C3-12cycloalkyl (e.g. cyclopropyl). According to yet another embodiment, specifically provided are compound of formula (I), in which R3is chloro, fluoro or cyclopropyl. According to yet another embodiment, specifically provided are compound of formula (I), in which ‘m’ is 0 or 1. According to yet another embodiment, specifically provided are compound of formula (I), in which R3is chloro, fluoro or cyclopropyl and ‘m’ is 0 or 1. According to yet another embodiment, specifically provided are compound of formula (I), in which two R3group combined together with the adjacent C or N atom to which they are attached, form a 5- to 6-membered fused heteroaryl ring which is unsubstituted or substituted by one or more R3a; wherein R3ais selected from C1-8alkyl (e.g. methyl). According to yet another embodiment, specifically provided are compound of formula (I), in which two R3group combined together with the adjacent C or N atom to which they are attached, form a 5- to 6-membered fused heteroaryl ring which is unsubstituted or substituted by one or more R3a; wherein R3ais selected from methyl. According to yet another embodiment, specifically provided are compound of formula (I), in which ‘Y’ is C or N. According to yet another embodiment, specifically provided are compound of formula (I), in which ‘Y’ is C. According to yet another embodiment, specifically provided are compound of formula (I), in which ‘Y’ is N. According to yet another embodiment, specifically provided are compound of formula (I), in which R5ais haloC1-8alkyl (e.g. trifluoroethyl), C1-8alkyl (e.g. methyl), C3-12cycloalkyl (e.g. cyclopropyl) or C3-8cycloalkylC1-8alkyl (e.g. cyclopropylmethyl). According to yet another embodiment, specifically provided are compound of formula (I), in which R5ais trifluoroethyl, methyl, cyclopropyl or cyclopropylmethyl. According to yet another embodiment, specifically provided are compound of formula (I), in which R5bis –CH(R6)-NR7R8. In this embodiment, R6is hydrogen; R7is hydrogen; R8is C1-8alkyl (e.g. isobutyl, neopentyl or isopentyl), C3-12cycloalkyl (e.g. cyclobutyl) or C3-8cycloalkylC1-8alkyl (e.g. cyclopropylmethyl) wherein C3-12cycloalkyl is substituted with one or more substituents selected from C1-8alkyl (e.g. methyl). According to yet another embodiment, specifically provided are compound of formula (I), in which R5bis –CH(R6)-NR7R8. In this embodiment, R6is hydrogen; R7is hydrogen; R8is isobutyl, neopentyl, isopentyl, 1-methylcyclobutyl or cyclopropylmethyl. According to yet another embodiment, specifically provided are compound of formula (I), in which of formula (I), in which R5bis –CH(R6)-NR7R8. In this embodiment, R6is hydrogen; and R7and R8joined together with the nitrogen atom to which they are attached, form a 3-15 membered heterocyclyl ), wherein 3-15 membered heterocyclyl is substituted with one or more from halogen (e.g. fluoro) or C1-8alkyl (e.g. methyl). According to yet another embodiment, specifically provided are compound of formula (I), in which R5bis –CH(R6)-NR7R8. In this embodiment, R6is hydrogen; and R7and R8joined together with the nitrogen atom to which they are attached, form a 3-15 membered heterocyclyl ), wherein 3-15 membered is heterocyclyl substituted with one or more from fluoro or methyl. According to yet another embodiment, specifically provided are compound of formula (I), in which According to yet another embodiment, specifically provided are compound of formula are (I), in which ‘n’ is 1. According to yet another embodiment, specifically provided are compound of formula are (I), in which R3is chloro, fluoro or cyclopropyl; Y is C or N; R5ais trifluoroethyl, methyl, cyclopropyl or cyclopropylmethyl; ‘t’ is 0, 1 or 2; ‘m’ is 0 or 1 and ‘n’ is 1. According to an embodiment, specifically provided are compound of formula (I) with an IC50 value of less than 500 nM, preferably, less than 100 nM, more preferably less than 50 nM, with respect to CBL-b inhibition activity. Further embodiments relating to groups ring A, ring B, X, Y, R1, R2, R3, R4, R5a, R5b, r, m, t and n (and groups defined therein) are described hereinafter in relation to the compound of formula (IA) or compound of Formula (IB) or compound of Formula (IC) or compound of Formula (ID). It is to be understood that these embodiments are not limited to use in conjunction with formula (IA), (IB), (IC) or (ID), but apply independently and individually to the compound of formula (I). For example, in an embodiment described hereinafter, the invention specifically provides compound of formula (IA), (IB), (IC) or (ID) in which R4is hydrogen and consequently there is also provided a compound of formula (I) in which R4is hydrogen. The invention also provides a compound of formula (IA), which is an embodiment of a compound of formula (I). or stereoisomer wherein, ring A is selected from ring B is selected from to 6-membered heteroaryl; X1and X2are independently represents C, N or S; ‘----’ between X1and X2represents optional bond; at each occurrence, R1is selected from halogen, C1-8alkyl, C1-8alkoxy, C1-8alkoxy-C1- 8alkyl, cyano, hydroxyl, haloC1-8alkyl and hydroxylC1-8alkyl; at each occurrence, R2is independently selected from halogen, haloC1-8alkyl, cyano, - COOH, -COO-C1-8alkyl, C1-8alkyl, C1-8alkoxy, C1-8alkoxy-C1-8alkyl, 4-6 membered heterocyclyl and C3-12cycloalkyl; wherein the said 4-6 membered heterocyclyl and C3- 8cycloalkyl are substituted with one or more substituents selected from halogen, cyano, hydroxyl, C1-8alkyl, haloC1-8alkyl, hydroxylC1-8alkyl, C1-8alkoxy and C1-8alkoxy-C1-8alkyl; at each occurrence, R3is independently selected from cyano, halogen, C1-8alkyl, haloC- 1-8alkyl, hydroxyl, hydroxylC1-8alkyl, C1-8alkoxy, C1-8alkoxy-C1-8alkyl, -COOH, -COO-C1-8alkyl, -NRxRy, C6-10aryl, 4-6 membered heterocyclyl and C3-12cycloalkyl; wherein the said C6-10aryl, 4-6 membered heterocyclyl and C3-8cycloalkyl are unsubstituted or substituted with one or more substituents selected from halogen, cyano, hydroxyl, C1-8alkyl, cyanoC1-8alkyl, haloC1-8alkyl, C1-8alkoxy, C1-8alkoxy-C1-8alkyl and hydroxylC1-8alkyl; alternatively, any two R3groups attached to the adjacent C or N atom combine together to form 5- to 6-membered fused heteroaryl ring which is unsubstituted or substituted by one or more R3a; R3ais independently selected from halogen, cyano, hydroxyl, C1-8alkyl, haloC1-8alkyl, hydroxylC1-8alkyl, C1-8alkoxy and C1-8alkoxy-C1-8alkyl; Rxand Ryare independently selected from hydrogen, C1-8alkyl, haloC1-8alkyl, hydroxylC1-8alkyl, cyanoC1-8alkyl, -COO-C1-8alkyl, S(O)2C1-8alkyl, C3-12cycloalkyl, 4-6 membered heterocyclyl and C3-8cycloalkylC1-8alkyl; wherein the said C3-12cycloalkyl, 4-6 membered heterocyclyl and C3-8cycloalkylC1-8alkyl are unsubstituted or substituted with one or more substituents selected from halogen, cyano, C1-8alkyl, haloC1-8alkyl, cyanoC1-8alkyl, hydroxyl and hydroxylC1-8alkyl; R5ais independently selected from halogen, C1-8alkyl, haloC1-8alkyl, C3-12cycloalkyl and C3-8cycloalkylC1-8alkyl; at each occurrence, R5bis independently selected from –CH(R6)-NR7R8; R6is selected from hydrogen; R7is selected from hydrogen; R8is selected from C1-8alkyl, C3-12cycloalkyl and C3-8cycloalkylC1-8alkyl; R7and R8joined together with the nitrogen atom to which they are attached, form a 3- 15 membered heterocyclyl; wherein 3-15 membered heterocyclyl is unsubstituted or substituted with one or more substituents selected from halogen and C1-8alkyl; ‘r’ is 0 or 1; ‘t’ is 0, 1 or 2; ‘m’ is 0, 1, 2 or 3; and ‘n’ is 1 or 2; The compound of formula (IA) may involve one or more embodiments. It is to be understood that the embodiments below are illustrative of the present invention and are not intended to limit the claims to the specific embodiments exemplified. It is also to be understood that the embodiments defined herein may be used independently or in conjunction with any definition, any other embodiment defined herein. Thus the invention contemplates all possible combinations and permutations of the various independently described embodiments. For example, the invention provides compound of formula (IA) as defined above wherein X1is C or N (according to another embodiment defined below) and X2is C or N (according to yet another embodiment defined below). According to one embodiment, specifically provided are compound of formula (IA), in which X1is C. According to another embodiment, specifically provided are compound of formula (IA), in which X1is N. According to yet another embodiment, specifically provided are compound of formula (IA), in which X1is C or N. According to yet another embodiment, specifically provided are compound of formula (IA), in which X2is C. According to yet another embodiment, specifically provided are compound of formula (IA), in which X2is N. According to yet another embodiment, specifically provided are compound of formula (IA), in which X2is C or N. According to yet another embodiment, specifically provided are compound of formula (IA), in which ring According embodiment, specifically provided are compound of formula (IA), in which ring According embodiment, specifically provided are compound of formula (IA), in which ring According embodiment, specifically provided are compound of formula (IA), in which ring According to yet are compound of formula (IA), in which R1is C1-8alkyl (e.g. methyl). According to yet another embodiment, specifically provided are compound of formula (IA), in which R1is methyl. According to yet another embodiment, specifically provided are compound of formula (IA), in which ‘r’ is 1. According to yet another embodiment, specifically provided are compound of formula (IA), in which R1is methyl and ‘r’ is 1. According to yet another embodiment, specifically provided are compound of formula (IA), in which ring B is divalent phenyl or divalent 5- to 6-membered embodiment, specifically provided are compound of formula (IA), in which ring According specifically provided are compound of formula (IA), in which R2is cyano, halogen (e.g. chloro or fluoro) or C1-8alkyl (e.g. methyl). According to yet another embodiment, specifically provided are compound of formula (IA), in which R2is cyano, chloro, fluoro or methyl. According to yet another embodiment, specifically provided are compound of formula (IA), in which ‘t’ is 0, 1 or 2. According to yet another embodiment, specifically provided are compound of formula (IA), in which R3is halogen (e.g. chloro or fluoro) or C3-12cycloalkyl (e.g. cyclopropyl). According to yet another embodiment, specifically provided are compound of formula (IA), in which R3is chloro, fluoro or cyclopropyl. According to yet another embodiment, specifically provided are compound of formula (IA), in which ‘m’ is 0 or 1. According to yet another embodiment, specifically provided are compound of formula (IA), in which R3is chloro, fluoro or cyclopropyl and ‘m’ is 0 or 1. According to yet another embodiment, specifically provided are compound of formula (IA), in which two R3group combined together with the adjacent C or N atom to which they are attached, form a 5- to 6-membered fused heteroaryl ring which is unsubstituted or substituted by one or more R3a; wherein R3ais selected from C1-8alkyl (e.g. methyl). According to yet another embodiment, specifically provided are compound of formula (IA), in which two R3group combined together with the adjacent C or N atom to which they are attached, form a 5- to 6-membered fused heteroaryl ring which is unsubstituted or substituted by one or more R3a; wherein R3ais selected from methyl. According to yet another embodiment, specifically provided are compound of formula are (IA), in which R5ais haloC1-8alkyl (e.g. trifluoroethyl), C1-8alkyl (e.g. methyl), C3-12cycloalkyl (e.g. cyclopropyl) or C3-8cycloalkylC1-8alkyl (e.g. cyclopropylmethyl). According to yet another embodiment, specifically provided are compound of formula (IA), in which R5ais trifluoroethyl, methyl, cyclopropyl or cyclopropylmethyl. According to yet another embodiment, specifically provided are compound of formula (IA), in which R5bis –CH(R6)-NR7R8. In this embodiment, R6is hydrogen; R7is hydrogen; R8is C1-8alkyl (e.g. isobutyl, neopentyl or isopentyl), C3-12cycloalkyl (e.g. cyclobutyl) or C3-8cycloalkylC1-8alkyl (e.g. cyclopropylmethyl) wherein C3-12cycloalkyl is substituted with one or more substituents selected from C1-8alkyl (e.g. methyl). According to yet another embodiment, specifically provided are compound of formula (IA), in which R5bis –CH(R6)-NR7R8. In this embodiment, R6is hydrogen; R7is hydrogen; R8is isobutyl, neopentyl, isopentyl, 1-methylcyclobutyl or cyclopropylmethyl. According to yet another embodiment, specifically provided are compound of formula formula (IA), in which R5bis –CH(R6)-NR7R8. In this embodiment, R6is hydrogen; and R7and R8joined together with the nitrogen atom to which they are attached, form a 3-15 membered heterocyclyl (e.g. ), wherein 3-15 membered heterocyclyl is substituted with one or more substituents selected from halogen (e.g. fluoro) or C1-8alkyl (e.g. methyl). According to yet another embodiment, specifically provided are compound of formula (IA), in which R5bis –CH(R6)-NR7R8. In this embodiment, R6is hydrogen; and R7and R8joined together with the nitrogen atom to which they are attached, form a 3-15 membered heterocyclyl (e.g. ), wherein 3-15 membered heterocyclyl is substituted with one or more substituents selected from fluoro or methyl. According to yet another embodiment, specifically provided are compound of formula specifically provided are compound of formula to yet are (IA), in which ‘n’ is 1. According to yet another embodiment, specifically provided are compound of formula are (IA), in which X1is C or N; X2is C or N; ring R1is methyl; ring R2 R3is chloro, fluoro or cyclopropyl; two R3group combined together with the adjacent C or N atom to which they are attached, form a 5- to 6-membered fused heteroaryl ring which is unsubstituted or substituted by one or more R3a; R3ais methyl; R5ais trifluoroethyl, methyl, cyclopropyl or cyclopropylmethyl; ‘t’ is 0, 1 or 2; ‘m’ is 0, 1, 2 or 3; and ‘n’ is 1. According to yet another embodiment, specifically provided are compound of formula (IA), in which Rais trifluoroethyl, methyl, cyclopropyl or cyclopropylmethyl; ‘t’ is 0, 1 or 2; and ‘n’ is 1. According to yet another embodiment, specifically provided are compound of formula (IA), in which , R is trifluoroethyl, methyl, cyclopropyl or cyclopropylmethyl; ‘t’ is 0, 1 or 2; and ‘n’ is 1. According to an embodiment, specifically provided are compound of formula (IA) with an IC50value of less than 500 nM, preferably, less than 100 nM, more preferably less than 50 nM, with respect to CBL-b inhibitor activity. The invention also provides a compound of formula (IB), which is an embodiment of a compound of formula (IA). Accordingly, the invention provides a compound of formula (IB) or a stereoisomer or a wherein, ring B, X1, X2, R1, R2, R3, R5a, R5b, m, t and n are as defined in formula (IA). According to yet another embodiment, specifically provided are compound of formula (IB), in which R1is methyl; ring B is or ; R2is cyano, chloro, fluoro or methyl; an are an IC50value of less than 1000 nM, preferably, less than 500 nM, more preferably less than 100 nM, with respect to CBL-b inhibition activity. The invention also provides a compound of formula (IC), which is an embodiment of a compound of formula (IA). Accordingly, the invention provides a compound of formula (IC) or a or a wherein, ring A, X1, X2, R1, R2, R3, R5a, R5b, r, m, t and n are as defined in formula (IA). According to yet another embodiment, specifically provided are compound of formula (IC), in which ring R1 R2is cyano, chloro, fluoro or methyl; ‘n’ is 1. According to an embodiment, specifically provided are compound of formula (IC) with an IC50 value of less than 1000 nM, preferably, less than 500 nM, more preferably less than 100 nM, with respect to CBL-b inhibition activity. The invention also provides a compound of formula (ID), which is an embodiment of a compound of formula (IA). Accordingly, the invention provides a compound of formula (ID) or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein, X2, R1, R2, R3, R5a, R5b, m, t and n are as defined in formula (IA). According to yet another embodiment, specifically provided are compound of formula (ID), in which R1is methyl; R2is cyano, chloro, fluoro or methyl; ‘n’ is 1. According to an embodiment, specifically provided are compound of formula (ID) with an IC50value of less than 1000 nM, preferably, less than 500 nM, more preferably less than 100 nM, with respect to CBL-b inhibition activity. Compounds of the present invention include the compounds in Examples 1-32. It should be understood that the formula (I), (IA), (IB), (IC) or (ID) structurally encompasses all geometrical isomers, stereoisomers, enantiomers and diastereomers, N-oxides, and pharmaceutically acceptable salts that may be contemplated from the chemical structure of the genera described herein. The present application also provides a pharmaceutical composition that includes at least one compound described herein and at least one pharmaceutically acceptable excipient (such as a pharmaceutically acceptable carrier or diluent). Preferably, the pharmaceutical composition comprises a therapeutically effective amount of at least one compound described herein. Pharmaceutical compositions comprising compounds of the present invention may be prepared using conventional diluents or excipients and techniques known in the art. Definitions: The terms “halogen” or “halo” means fluorine (fluoro), chlorine (chloro), bromine (bromo), or iodine (iodo). The term “alkyl” refers to a hydrocarbon chain radical that includes solely carbon and hydrogen atoms in the backbone, containing no unsaturation, having from one to eight carbon atoms (i.e. C1-8alkyl), and which is attached to the rest of the molecule by a single bond, such as, but not limited to, methyl, ethyl, n-propyl, 1-methylethyl (isopropyl), n-butyl, n-pentyl, and 1,1-dimethylethyl (t-butyl). The term “C1-6alkyl” refers to an alkyl chain having 1 to 6 carbon atoms. The term “C1-4alkyl” refers to an alkyl chain having 1 to 4 carbon atoms. The term “alkoxy” denotes an alkyl group attached via an oxygen linkage to the rest of the molecule. Representative examples of such groups are –OCH3 and –OC2H5. The term “cyanoalkyl” refers to cyano group, linked to an alkyl group as defined above (i.e. cyanoC1-8alkyl). Examples of such haloalkyl moiety include, but are not limited to, cyanomethyl, cyanoethyl and cyanopropyl groups. The term “haloalkyl” refers to at least one halo group (selected from F, Cl, Br or I), linked to an alkyl group as defined above (i.e. haloC1-8alkyl). Examples of such haloalkyl moiety include, but are not limited to, trifluoromethyl, difluoromethyl and fluoromethyl groups. The term “haloC1-8alkyl” refers to at least one halo group linked an alkyl chain having 1 to 8 carbon atoms. The term “alkoxy” denotes an alkyl group attached via an oxygen linkage to the rest of the molecule (i.e. C1-8 alkoxy). Representative examples of such groups are –OCH3 and – OC2H5. The term “alkoxyalkyl” or “alkyloxyalkyl” refers to an alkoxy or alkyloxy group as defined above directly bonded to an alkyl group as defined above (i.e. C1-8alkoxyC1-8alkyl or C1-8alkyloxyC1-8alkyl). Example of such alkoxyalkyl moiety includes, but are not limited to, - CH2OCH3 (methoxymethyl) and -CH2OC2H5 (ethoxymethyl). Unless set forth or recited to the contrary, all alkoxyalkyl groups described herein may be straight chain or branched. The term “hydroxyC1-8alkyl” refers to a C1-8alkyl group as defined above wherein one to three hydrogen atoms on different carbon atoms is / are replaced by hydroxyl groups (i.e. hydroxyC1-4alkyl). Examples of hydroxyC1-4alkyl moieties include, but are not limited to – CH2OH and –C2H4OH. The term “cycloalkyl” denotes a non-aromatic mono or multicyclic ring system of 3 to about 12 carbon atoms, (i.e.C3-12cycloalkyl). Examples of monocyclic cycloalkyl include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Examples of multicyclic cycloalkyl groups include, but are not limited to, perhydronapthyl, 27yridine27 and norbornyl groups, bridged cyclic groups or spirobicyclic groups, e.g., spiro(4,4)non-2-yl. The term “C3-6cycloalkyl” refers to the cyclic ring having 3 to 6 carbon atoms. Examples of “C3-6cycloalkyl” include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. The term “cycloalkylalkyl” refers to a cyclic ring-containing radical having 3 to about 6 carbon atoms directly attached to an alkyl group (i.e. C3-6cycloalkylC1-8alkyl). The cycloalkylalkyl group may be attached to the main structure at any carbon atom in the alkyl group that results in the creation of a stable structure. Non-limiting examples of such groups include cyclopropylmethyl, cyclobutylethyl, and cyclopentylethyl The term “aryl” refers to an aromatic radical having 6 to 14 carbon atoms (i.e. C6-14aryl), including monocyclic, bicyclic and tricyclic aromatic systems, such as phenyl, naphthyl, tetrahydronapthyl, indanyl, and biphenyl. In one embodiment, the term “C6-10aryl” refers to an aromatic radical having 6 to 10 carbon atoms. The term “heterocyclic ring” or “heterocyclyl” unless otherwise specified refers to substituted or unsubstituted non-aromatic 3 to 15 membered ring radical (i.e.3 to 15 membered heterocyclyl) which consists of carbon atoms and from one to five hetero atoms selected from nitrogen, phosphorus, oxygen and sulfur. The heterocyclic ring radical may be a mono-, bi- or tricyclic ring system, which may include fused, bridged or spiro ring systems, and the nitrogen, phosphorus, carbon, oxygen or sulfur atoms in the heterocyclic ring radical may be optionally oxidized to various oxidation states. In addition, the nitrogen atom may be optionally quaternized; also, unless otherwise constrained by the definition the heterocyclic ring or heterocyclyl may optionally contain one or more olefinic bond(s). Examples of such heterocyclic ring radicals include, but are not limited to azepinyl, azetidinyl, oxetanyl, benzodioxolyl, benzodioxanyl, chromanyl, dioxolanyl, dioxaphospholanyl, decahydroisoquinolyl, indanyl, indolinyl, isoindolinyl, isochromanyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, oxazolinyl, oxazolidinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2- oxopyrrolidinyl, 2-oxoazepinyl, octahydroindolyl, octahydroisoindolyl, perhydroazepinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, piperidinyl, phenothiazinyl, phenoxazinyl, quinuclidinyl, tetrahydroisquinolyl, tetrahydrofuryl or tetrahydrofuranyl, tetrahydropyranyl, thiazolinyl, thiazolidinyl, thiamorpholinyl, thiamorpholinyl sulfoxide and thiamorpholinyl sulfone. The heterocyclic ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure. In one embodiment, the term “heterocyclyl ring” refers to 4 to 6 membered ring radical (i.e.4- to 6-membered heterocyclyl). The term “heterocyclylalkyl” refers to a heterocyclic ring radical directly bonded to an alkyl group (i.e. heterocyclylC1-8alkyl). The heterocyclylalkyl radical may be attached to the main structure at any carbon atom in the alkyl group that results in the creation of a stable structure. The term “heteroaryl” unless otherwise specified refers to 5 to 14 membered aromatic heterocyclic ring radical with one or more heteroatom(s) independently selected from N, O or S (i.e. 5 to 14 membered heteroaryl). The heteroaryl may be a mono-, bi- or tricyclic ring system. The heteroaryl ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure. Examples of such heteroaryl ring radicals include, but are not limited to oxazolyl, isoxazolyl, imidazolyl, furyl, indolyl, isoindolyl, pyrrolyl, triazolyl, triazinyl, tetrazoyl, thienyl, oxadiazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrazolyl, benzofuranyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, benzothienyl, benzopyranyl, carbazolyl, quinolinyl, isoquinolinyl, quinazolinyl, cinnolinyl, naphthyridinyl, pteridinyl, purinyl, quinoxalinyl, quinolyl, isoquinolyl, thiadiazolyl, indolizinyl, acridinyl, phenazinyl and phthalazinyl. The term “pharmaceutically acceptable salt” includes salts prepared from pharmaceutically acceptable bases or acids including inorganic or organic bases and inorganic or organic acids. Examples of such salts include, but are not limited to, acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, pyridinee, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, oleate, oxalate, pamoate (embonate), palmitate, pantothenate, phosphate, diphosphate, polygalacturonate, salicylate, stearate, sulfate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide and valerate. Examples of salts derived from inorganic bases include, but are not limited to, pyridine, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, mangamous, potassium, sodium, and zinc. The term “treating” or “treatment” of a state, disorder or condition includes: (a) preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in a subject that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition; (b) inhibiting the state, disorder or condition, i.e., arresting or reducing the development of the disease or at least one clinical or subclinical symptom thereof; or (c) relieving the disease, i.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms. The term “subject” includes mammals (especially humans) and other animals, such as domestic animals (e.g., household pets including cats and dogs) and non-domestic animals (such as wildlife). A “therapeutically effective amount” means the amount of a compound that, when administered to a subject for treating a state, disorder or condition, is sufficient to effect such treatment. The “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, weight, physical condition and responsiveness of the subject to be treated. The compound of formula (I), (IA), (IB), (IC) and (ID) may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compound of formula (I), (IA), (IB), (IC) and (ID) as well as mixtures thereof, including racemic mixtures, form part of the present invention. In addition, the present invention embraces all geometric and positional isomers. Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and / or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher’s acid chloride), separating the diastereomers and converting (e.g., hydrolysing) the individual diastereomers to the corresponding pure enantiomers. Enantiomers can also be separated by use of chiral HPLC column. The chiral centres of the present invention can have the S or R configuration as defined by the IUPAC 1974. The terms “salt” or “solvate”, and the like, is intended to equally apply to the salt, solvate and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers or racemates of the inventive compounds. PHARMACEUTICAL COMPOSITIONS The compounds of the present invention are typically administered in the form of a pharmaceutical composition. Such compositions can be prepared using procedures well known in the pharmaceutical art and comprise at least one compound of the invention. The pharmaceutical compositions described herein comprise one or more compounds described herein and one or more pharmaceutically acceptable excipients. METHODS OF TREATMENT The compounds of the present invention are particularly useful because they inhibit the activity of CBL-b, i.e., they prevent, inhibit, or suppress the action of CBL-b, and / or may elicit a CBL-b modulating effect. Compounds of the invention are therefore useful in the treatment of those conditions in which inhibition of CBL-b activity, and particularly CBL-b inflammasome, is beneficial. The compounds of the present application provide a method for treating a disease or disease mediated by CBL-b in a mammal, comprising administering a therapeutically effective amount of a compound of formula (I), compound of formula (IA) or compound of formula (IB) or compound of formula (IC) or compound of formula (ID) or a stereoisomer or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, to a mammal in need of the treatment, preferably a human. According to one embodiment, the compounds of the present patent application are inhibiting CBL-b activity and can be useful in the treatment of diseases or disorder mediated by CBL-b. According to another embodiment, the compounds of the invention may be useful in the treatment of cancer mediated by CBL-b. According to yet another embodiment, provided herein is a method of treating cancer responsive to inhibition of Cbl-b activity, the method comprising administering an effective amount of a compounds of the present invention provided herein to an individual to treat the cancer responsive to inhibition of Cbl-b activity. According to yet another embodiment, the compounds of the present invention for the use of treatment of cancer. According to yet another embodiment, the compounds of the present invention can be used in methods of modulating the immune system, such as increasing activation of T-cells, NK-cells and B-cells, as well as in the treatment of such cells in vivo, in vitro, or ex vivo. In one embodiment, the present inventions provide the use of the compounds described herein in the preparation of a medicament. In another embodiment, the present inventions provide the use of the compounds described herein in the preparation of a medicament for the treatment of diseases mediated by CBL-b. Any of the methods of treatment described herein comprise administering an effective amount of a compound according to formula (I), (IA), (IB), (IC) or (ID) or a pharmaceutically acceptable salt thereof, to a subject (particularly a human) in need thereof. The compounds of the invention are effective both in the therapeutic and / or prophylactic treatment of the above-mentioned conditions. GENERAL METHODS OF PREPARATION The compounds, described herein, including those of general formula (I), (IA), (IB), (IC), (ID), intermediates and specific examples are prepared through the synthetic methods as depicted in synthetic schemes 1-3. Furthermore, in the following schemes, where specific acids, bases, reagents, coupling reagents, solvents, etc. are mentioned, it is understood that other suitable acids, bases, reagents, coupling reagents, solvents etc. may be used and are included within the scope of the present invention. The modifications to reaction conditions, for example, temperature, duration of the reaction or combinations thereof, are envisioned as part of the present invention. The compounds obtained using the general reaction sequences may be of insufficient purity. These compounds can be purified using any of the methods for purification of organic compounds known to persons skilled in the art, for example, crystallization or silica gel or alumina column chromatography using different solvents in suitable ratios. All possible geometrical isomers and stereoisomers are envisioned within the scope of this invention. General Scheme A general approach for the preparation of general compounds of the formula (IA’) (wherein ring A, ring B, X1, X2, R1, R2, R3, R5a, R5b, R7, R8, ‘r’, ‘t’ and ‘m’ are as defined in the general description) is depicted in synthetic scheme 1. Synthetic scheme 1 The amines (1) gives the compound of formula (3). The coupling reaction is carried out in presence of suitable coupling reagents. The suitable coupling reagents used in the reaction may be selected from HATU, EDC.HCl, HOBt, DCC or T3P. The coupling reaction is carried out in presence of suitable aprotic solvent. The suitable aprotic solvent used in the reaction may be selected form dichloromethane, THF or dimethylformamide. The coupling reaction is carried out in presence of suitable base. The suitable base used in the reaction may be DIPEA or TEA. The compound of formula (3) upon oxidative cleavage in presence of protic solvent yields aldehyde compound of formula (4). The reaction is carried out in presence of suitable reagent. The suitable reagents used in the reaction may be selected from osmium tetraoxide or sodium periodate. The protic solvent used in the reaction may be selected from THF, water or mixture thereof. The reductive amination reaction of compound of formula (4) with appropriate amine the compound of formula (5) in a suitable solvent using suitable base and reducing agent in presence of suitable catalyst yields the compound of formula (IA’). The suitable catalyst used in the reaction may be acetic acid. The suitable base is used in the reaction may be selected from triethylamine or DIPEA. The reaction may be carried out in presence of a suitable aprotic solvent. The suitable aprotic solvent used in the reaction is such as dichloromethane or dimethylformamide. The reductive reaction is carried out in presence of suitable polar solvents. The suitable polar solvents used in the reaction may be selected from methanol or ethanol. The reaction is carried out in presence of suitable reducing agent. The suitable reducing agent used in the reaction may be selected from sodium borohydride, sodium triacetoxyborohydride or sodium cyanoborohydride. A general approach for the preparation of compounds of the general formulae (IA’) (wherein ring A, ring B, X1, X2, R1, R2, R3, R5a, R5b, R7, R8, ‘r’, ‘t’ and ‘m’ are as defined in the description) is depicted in synthetic scheme 2. Synthetic scheme 2 The (6) using coupling reagents in a suitable solvent and base yields the compound of formula (7). The coupling reagents used in the reaction may be selected from HATU, EDC.HCl, HOBt or DCC. The reaction may be carried out in a suitable aprotic solvent such as dichloromethane, THF or dimethylformamide and suitable base used in the reaction may be selected from DIPEA or TEA. The compound of formula (7) upon oxidative cleavage in presence of protic solvent yields aldehyde compound of formula (8). The suitable reagents used in the reaction may be selected from osmium tetraoxide or sodium periodate. The protic solvent used in the reaction may be selected from THF, water or mixture thereof. The reductive amination reaction of compound of formula (8) with appropriate amines (5) in a suitable solvent using suitable base and reducing agent in presence of suitable catalyst yields the compound of formula (9). The suitable catalyst used in the reaction may be acetic acid. The suitable base is used in the reaction may be selected from triethylamine or DIPEA. The reaction may be carried out in presence of a suitable aprotic solvent. The suitable aprotic solvent used in the reaction is such as dichloromethane or dimethylformamide. The reductive reaction is carried out in presence of suitable polar solvents. The suitable polar solvents used in the reaction may be selected from methanol or ethanol. The reaction is carried out in presence of suitable reducing agent. The suitable reducing agent used in the reaction may be selected from sodium borohydride, sodium triacetoxyborohydride or sodium cyanoborohydride. The borylation reaction of compound of formula (9) using bis(pinacolato)diboron yields the compound of formula (10). The reaction is carried out in the presence of suitable base. The suitable base used in the reaction may be potassium acetate, sodium carbonate or cesium carbonate. The reaction is carried out in the presence of suitable palladium catalyst. The suitable palladium catalyst used in the reaction may be 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane, or Dichlorobis(triphenyl phosphine)palladium(II). The reaction is carried out in the presence of suitable solvent. The suitable solvent used in the reaction may be selected from 1,4-dioxane, toluene or DMA. The Suzuki coupling reaction of compound of formula (10) with the compound of formula (11) yields the compound of formula (IA’). The Suzuki reaction is carried out in the presence of suitable base, catalyst and solvent. The suitable base used in the reaction may be potassium phosphate, potassium carbonate, sodium carbonate or cesium carbonate. The reaction is carried out in the presence of suitable palladium catalyst. The suitable palladium catalyst used in the reaction may be tetrakis (triphenyl phosphine) palladium(0) or 1,1′-bis(diphenylphosphino)ferrocene] dichloro palladium(II) complex with dichloromethane. The reaction is carried out in the presence of suitable solvent. The solvent used in the reaction may be selected from ethanol, toluene, 1,4-dioxane, DMSO, water or a combination thereof. A general approach for the preparation of intermediate of the general formulae (2) (wherein R5ais as defined in the description) is depicted in synthetic scheme 3. Synthetic scheme 3
[0002] The esterification of compound of formula (12) in a suitable polar solvent such as methanol or ethanol yields ester compound of formula (13) (wherein R = C1-8alkyl). Selective N-Alkylation of compound of formula (13) with suitable alkylating agents (R5a-X, where X = Br, I or trifluoromethane sulfate) in the presence of suitable base and solvent yields the compound of formula (14). The suitable base used in the reaction may be selected from cesium carbonate, potassium carbonate, sodium carbonate or sodium hydride. The suitable solvent may be selected from DMSO, DMF, THF or combination thereof. Alternatively, N-alkylated compound of formula (14) can also be synthesized from compound of formula (13) and alkyl boronic acid using Chan-Lam coupling procedure. The reaction is performed using suitable catalyst, ligand and base in the appropriate solvent under oxygen atmosphere. The suitable catalyst used in the reaction is Copper (II) acetate, Bipyridine as ligand and sodium carbonate used as base. The suitable solvent may be selected from 1,2-dichloroethane, 1,2- dichloromethane, 1,4-dioxane or mixture thereof. The Suzuki coupling reaction of compound of formula (14) and potassium vinyl trifluoroborate in the presence of suitable base, catalyst and solvent yields the compound of formula (15). The suitable base used in the reaction may be selected from potassium phosphate, potassium acetate, sodium, potassium tert-butoxide, sodium carbonate or cesium carbonate. The suitable catalyst used in the reaction may be selected from tetrakis(triphenylphosphine)palladium(0) or 1,1′- bis(diphenylphosphino)ferrocene]dichloropall adium(II) complex with dichloromethane, along with a suitable phosphine ligand. The coupling reaction may be carried out in a suitable polar solvent or combination thereof. The suitable solvent may be selected from ethanol, toluene, 1,4-dioxane, DMSO, water or a combination thereof. The hydrolysis reaction of compound of formula (15) gives the compound of formula (2). The reaction is carried out in presence of suitable base. The suitable base used in the reaction may be selected from lithium hydroxide, sodium hydroxide or potassium hydroxide. The reaction is carried out in presence of suitable polar solvent. The suitable polar solvent used in the reaction may be selected from water, methanol, ethanol or tetrahydrofuran or combination thereof. EXPERIMENTAL SECTION Unless otherwise stated, work-up includes distribution of the reaction mixture between the organic and aqueous phase indicated within parentheses, separation of layers and drying the organic layer over sodium sulfate, filtration and evaporation of the solvent. Purification, unless otherwise mentioned, includes purification by silica gel chromatographic techniques, generally using ethyl acetate / petroleum ether mixture of a suitable polarity as the mobile phase. Use of a 20 different eluent system is indicated within parentheses. The abbreviations, symbols and terms used in the examples have the following meanings throughout: Abbreviations Full Form H2SO4Sulfuric acid NaOH Sodium hydroxide HCl Hydrochloric acid DCM Dichloromethane H2O2Hydrogen peroxide K2CO3Potassium carbonate Pd(PPh3)4Tetrakis(triphenylphosphine)palladium(0) DMF N,N-Dimethylformamide HATU Hexafluorophosphate Azabenzotriazole Tetramethyl Uronium DIPEA N,N-Diisopropylethylamine AcOH Acetic acid NaHCO3 Sodium bicarbonate K3PO4 Tripotassium phosphate THF Tetrahydrofuran RT Room temperature Pd / C Palladium on carbon KOAc Potassium acetate Pd(dppf)Cl2.DC [1,1'-Bis(diphenylphosphino)ferrocene]palladium(II M ) dichloride, complex with dichloromethane Na2CO3Sodium carbonate PCy3Tricyclohexyl phosphine Pd2(dba)3Tris(dibenzylidene acetone)dipalladium(0) EtOAc Ethyl Acetate Na2SO4Sodium sulfate NaH Sodium hydride NH4Cl Ammonium Chloride Abbreviations Full Form LiOH Lithium hydroxide MeOH Methanol NaIO4Sodium periodate OsO4Osmium tetroxide NaI Sodium iodide Fe Iron TEA Triethylamine Cu(OAc)2 Copper(II) acetate t-BuOH tert-Butyl alcohol DCE Dichloroethane N2Nitrogen INTERMEDIATES Intermediate A1 4'-Fluoro-2'-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-3-amine g, 22.83 mmol) in methanol (50 mL) was added conc. H2SO4(5 mL) dropwise and stirred at 90 °C for 16 h. The reaction mixture was concentrated under reduced pressure and neutralized with saturated sodium bicarbonate solution and extracted twice with ethyl acetate. The organic layer was separated, dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain 4.2 g of the desired product.1H NMR (400 MHz, DMSO-d6) ^ 3.87 (s, 3H), 7.38 - 7.43 (m, 1H), 7.63 – 7.66 (dd, J = 5.6 Hz, J =8.8 Hz ,1H), 7.78 - 7.82 (m, 1H). Step-2: 2-Bromo-5-fluorobenzohydrazide To a stirred solution of methyl 2- (600 mg, 2.57 mol) in methanol (1 mL) was added hydrazine hydrate (412 mg, 12.87 mol) dropwise at 0 °C and stirred for 5 min. The reaction mixture was stirred at 90 °C for 2 h. The reaction mixture was cooled to RT. The precipitated obtained was washed with water and dried under vacuum to obtain 530 mg of the desired product.1H NMR (400 MHz, DMSO-d6) ^ 4.50 (s, 2H), 7.24 – 7.28 (m, 2H), 7.69 - 7.70 (m, 1H), 9.62 (s, 1H); ESI-MS (m / z) 235 (M+2H)+. Step-3: 5-(2-Bromo-5-fluorophenyl)-4-methyl-4H-1,2,4-triazole-3-thiol To a stirred solution of 2-bromo-5- (530 mg, 2.27 mol) in methanol (10 mL) was added Methylisothiocyanate (211 mg, 2.72 mol) and stirred at RT for 16 h. The 2N NaOH solution (384 mg, 9.6 mol) was added and stirred at 90 °C for 2 h. The reaction mixture was cooled to RT and acidified with 1N HCL (pH ~ 2). The solid precipitated was filtered and dried under pressure to obtain 550 mg of the desired product.1H NMR (400 MHz, DMSO-d6) ^ 3.26 (s, 3H), 7.48 - 7.57 (m, 1H), 7.65 – 7.68 (m, 1H), 7.87 - 7.93 (m, 1H), 14.08 (s, 1H); ESI-MS (m / z) 290 (M+2H)+. Step-4: 3-(2-Bromo-5-fluorophenyl)-4-methyl-4H-1,2,4-triazole To a stirred solution of 5-(2-bromo-5- -4-methyl-4H-1,2,4-triazole-3-thiol (550 mg, 1.90 mol) and acetic acid (3.42 g, 3 mL, 57 mol) in DCM (10 mL) was cooled to 0 °C and added dropwise H2O2 (30% in water) (646 mg, 0.19 mL, 19.0 mol). The reaction mixture was stirred at 0 °C for 2 h. The reaction mixture was concentrated under reduced pressure and diluted with ethyl acetate. The organic layer was washed twice with water followed by sodium bicarbonate solution and separated the organic layer. The organic layer was dried over Na2SO4 and concentrated under reduced pressure. The residue obtained was purified using silica gel column chromatography to obtain 190 mg of the desired product.1H NMR (400 MHz, DMSO- d6) ^ 3.50 (s, 3H), 7.42 – 7.48 (m, 1H), 7.50 - 7.53 (m, 1H), 7.87-7.90 (m,1H), 8.66 (s, 1H), ESI-MS (m / z) 258 (M+2H)+. Step-5: 4'-Fluoro-2'-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-3-amine To a stirred solution of 3-(2-bromo-5-fluorophenyl)-4-methyl-4H-1,2,4-triazole (200 mg, 0.78 mol), 3-Aminophenylboronic acid (128 mg, 0.93 mol) and K2CO3 (323 mg, 2.34 mol) in 1,4- Dioxane (5 mL) and water (1 mL) was degassed using nitrogen for 10 min. To this reaction mixture was added Pd(PPh3)4(360 mg, 0.31 mol) and again degassed for 5 min and heated to 120 °C for 3 h. The reaction mixture was diluted with water and extracted twice with ethyl acetate. The organic layer was separated, dried over anhydrous Na2SO4and concentrated under vacuum. The product obtained was triturated with diethyl ether to obtain 150 mg of the desired product.1H NMR (400 MHz, DMSO-d6) ^ 3.00 (s, 3H), 5.12 (s, 2H), 6.13 (d, J = 7.6 Hz, 1H), 6.37 (s, 1H), 6.47 (d, J = 8 Hz, 1H), 6.91 (t, J = 7.6 Hz, 1H), 7.38 – 7.35 (m, 1H), 7.63 - 7.47 (m, 2H), 8.41 (s, 1H); ESI-MS (m / z) 269 (M+H)+. The analytical data of the intermediate prepared by following the procedure described above are given in below Table 1. Table 1: Structure, Chemical Name and analytical data of Intermediates (A2-A11) Intermediate Structure and Chemical Name Analytical data No. 1H NMR (400 MHz, DMSO-d6) ^ A2 2.97 (s, 3H), 5.10 (s,2H), 6.15 (d, J=7.6Hz,1H), 6.40 (s,1H), 6.47- 2'-(4-Methyl-4H-1,2,4-triazol-3- 6.49 (m,1H), 6.91 (t, J=8.0Hz, 1H), yl)-[1,1'-biphenyl]-3-amine 7.49-7.52 (m,3H), 7.61- 7.65(m,1H), 8.38 (s,1H); ESI-MS (m / z) 251 (M+H)+A31H NMR (400 MHz, DMSO-d6) ^ 2.93 (s, 3H), 3.68 (s,2H), 6.46 (s,1H), 6.63 (s,2H),7.09 (t, J=8.0 Hz,1H),7.19 (m,1H), 7.28 (d, J=8.0 5'-Fluoro-2'-(4-methyl-4H-1,2,4- Hz, 1H), 7.64 (d, J=8.4Hz, 1H), triazol-3-yl)-[1,1'-biphenyl]-3- 8.01 (s,1H); amine A41H NMR (400 MHz, DMSO-d6) ^ 3.05 (s, 3H), 5.19 (s, 2H), 6.16 – 6.12 (m, 1H), 6.57 – 6.54 (m, 1H), 6.91 – 6.86 (m, 1H), 7.39 – 7.37 (m, 4,4'-Difluoro-2'-(4-methyl-4H- 1H), 7.56 - 7.49 (m, 2H), 8.43 (s, 1,2,4-triazol-3-yl)-[1,1'-biphenyl]- 1H); 3-amine Intermediate Structure and Chemical Name Analytical data No. A51H NMR (400 MHz, DMSO-d6) ^ 3.09 (s, 3H), 5.40 (s, 2H), 6.17 – 6.15 (m, 1H), 6.58 (s, 1H), 7.08 (d, J = 8.4 Hz, 1H), 7.43 – 7.39 (m, 4-Chloro-4'-fluoro-2'-(4-methyl- 1H), 7.65 - 7.51 (m, 2H), 8.44 (s, 4H-1,2,4-triazol-3-yl)-[1,1'- 1H) biphenyl]-3-amine A61H (400 MHz, CDCl3) ^ 3.06 (s, 3H), 5.27(s, 2H), 6.18-6.22 (m, 1H), 6.59(dd, J1=2.4 Hz, J2=8.8 Hz 1H), 6.92-6.97 (m,1H), 7.71 (d, 3'-Amino-4'-fluoro-2-(4-methyl- J=8Hz 1H), 8.01 (d, J = 1.6Hz, 1H), 4H-1,2,4-triazol-3-yl)-[1,1'- 8.10 (dd, J1=1.6Hz, J2=8.0 Hz 1H), biphenyl]-4-carbonitrile 8.46 (s, 1H). A71H NMR (400 MHz, DMSO-d6) ^ 3.18 (s, 3H), 5.96 (s, 2H), 6.10 (t, J = 1.2 Hz, 1H),6.19 (s, 1H), 7.44- 7.47 (m,1H),7.54-7.62 (m, 2H), 4-(4-Fluoro-2-(4-methyl-4H-1,2,4- 7.78 (d, J = 5.2 Hz, 1H), 8.48 (s, triazol-3-yl)phenyl)pyridin-2-amine 1H) A81H NMR (400 MHz, DMSO-d6) ^ 3.11(s, 3H), 5.48 (bs, 2H), 5.90 (d, J=9.6 Hz, 1H), 6.16 (s, 1H), 6.24 (d, J=11.6 Hz, 1H), 7.40 (dd, J1=2.4 4',5-Difluoro-2'-(4-methyl-4H- Hz, J2= 2.4 Hz, 1H), 7.50-7.53 (m, 1,2,4-triazol-3-yl)-[1,1'-biphenyl]- 1H), 7.55-7.59 (m, 1H), 8.46 (s, 3-amine 1H) A91H NMR (400 MHz, DMSO-d6) ^ 3.25 (s, 3H), 5.13 (s, 2H), 6.11-6.14 Intermediate Structure and Chemical Name Analytical data No. 2,4'-Difluoro-2'-(4-methyl-4H- (m, 1H), 6.66-6.72 (m, 2H), 7.61- 1,2,4-triazol-3-yl)-[1,1'-biphenyl]- 7.47 (m, 3H), 8.43 (s, 1H) 3-amine A101H NMR (400 MHz, DMSO-d6) ^ 2.99 (s, 3H), 5.14 (s, 2H),6.13 (d, J = 7.6 Hz, 1H), 6.37 (s, 1H), 6.48 – 6.50 (m, 1H), 6.90 – 6.92 (m, 1H), 4'-Chloro-2'-(4-methyl-4H-1,2,4- 7.52 – 7.57 (m, 2H), 7.69 – 7.76 (m, triazol-3-yl)-[1,1'-biphenyl]-3- 1H), 8.42 (s, 1H); ESI-MS (m / z) amine 285.1 (M+H)+. A111H NMR (400 MHz, DMSO-d6) ^ 3.01 (s, 3H), 5.14 (bs, 2H), 6.15 (d, J= 7.6 Hz,1H), 6.35-6.36 (m, 1H), 6.49-6.51 (m, 1H), 6.92(t, J= 8 Hz, 4',5'-Difluoro-2'-(4-methyl-4H- 1H),7.57-7.66 (m, 2H), 8.42 (s, 1,2,4-triazol-3-yl)-[1,1'-biphenyl]- 1H); ESI-MS (m / z) 287.2 (M+ H)+. 3-amine Intermediate A12 3'-Amino-2-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-4-carbonitrile Step-1: 2-Bromo-5-iodo benzoic acid To a stirred solution of 2-bromobenzoic mmol) in Conc. H2SO4(100 mL) was added N-iodo succinimide (3.7 g, 16.41 mmol) portion wise at 0 °C for 30 min and then stirred at RT for 16 h. The reaction mixture was poured in ice water. The reaction mixture was filtered and the residue obtained was dissolved in ethyl acetate and washed with 1% aqueous sodium thiosulfate. The organic layer was separated, dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain 4.5 g of the desired product.1H NMR (400 MHz, DMSO- d6): δ 7.49(d, J= 8.4 Hz,1H), 7.60(d, J=8.4 Hz, 1H), 8.02 (s, 1H), 13.66 (bs, 1H); ESI-MS (m / z) 324.9 (M-H)+. Step-2: 2-(2-Bromo-5-iodobenzoyl)-N-methylhydrazine-1-carbothioamide To a stirred solution of 2-bromo-5- g, 13.76 mmol) in DMF (25 mL) was added HATU (7.8 g, 20.64 mmol), DIPEA (5.3 g, 41.28 mmol) and stirred at 5-10 °C for 20 min and 4-methyl-3-thiosemicarbazide (2.16 g, 20.64 mmol) was added to the reaction mixture. The reaction mixture was stirred at RT for 16 h. The reaction mixture was diluted with water, acidified with dilute HCl. The solid precipitated was filtered and dried under vacuum. The solid obtained was stirred in diethyl ether for 30 min, filtered and dried under vacuum to obtain 3 g of the desired product which was used for next step without purification. ESI-MS (m / z) 415.0 (M+2H)+. Step-3: 5-(2-Bromo-5-iodophenyl)-4-methyl-4H-1,2,4-triazole-3-thiol To a stirred suspension of 2-(2- -N-methylhydrazine-1-carbothioamide (3 g, 7.28 mmol) in 1 N aqueous NaOH (100 mL) was heated to 70-80 °C for 18 h. The reaction mixture was cooled to RT and acidified with dilute HCl and stirred for 30 min. The solid precipitated was filtered, dried and purified by silica gel column chromatography to yield 1.85 g of the desired product.1HNMR (400 MHz, DMSO-d6): δ 3.25 (s, 3H), 7.63(d, J= 8.4 Hz,1H), 7.90(d, J=8.4 Hz, 1H), 8.02 (s, 1H), 14.04 (bs, 1H); ESI-MS (m / z) 397.2 (M+H)+. Step-4: 3-(2-Bromo-5-iodophenyl)-4-methyl-4H-1,2,4-triazole To a stirred suspension of 5-(2-bromo-5- -4-methyl-4H-1,2,4-triazole-3-thiol (1.85 g, 4.67 mmol) in DCM (30 mL) and AcOH (3.9 g, 65.4 mmol) was added 30% H2O2 solution (370 mg, 10.89 mmol) at 0 °C. The mixture was stirred at RT for 16 h. The reaction mixture was quenched with water, basified with aq NaHCO3and extracted twice with DCM. The solvent was concentrtaed under reduced pressure and the solid obtained was purified by silica gel column chromatography to yield 1.3 g of the desired product.1HNMR (400 MHz, DMSO- d6): δ 3.49 (s, 3H), 7.61(d, J= 8.8 Hz,1H), 7.86-7.88(m, 2H), 8.64 (s, 1H); ESI-MS (m / z) 366.1 (M+2H)+. Step-5: 4-Bromo-3-(4-methyl-4H-1,2,4-triazol-3-yl)benzonitrile To a stirred suspension of 3-(2-bromo- -4-methyl-4H-1,2,4-triazole (1.4 g, 3.86 mmol) in DMF (20 mL) was added Zinc(II)cyanide (774 mg, 6.6 mmol), Pd(PPh3)4 and heated to 130-140 °C for 16 h. The reaction mixture was cooled to RT, diluted with ethyl acetate and filtered. The filtrate was concentrated under reduced pressure and the solid obtained was purified by silica gel column chromatography to yield 510 mg of the desired product.1HNMR (400 MHz, DMSO-d6): δ 3.51 (s, 3H), 8.01(d, J= 8.8 Hz,1H), 8.08-8.10(m, 2H), 8.69 (s, 1H); ESI-MS (m / z) 263.1 (M+2H)+. Step 6: 3'-Amino-2-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-4-carbonitrile To a stirred degassed solution of 4-bromo-3-(4-methyl-4H-1,2,4-triazol-3-yl)benzonitrile (230 mg, 0.874 mmol), 3-amino phenyl boronic acid (239 mg, 1.75 mmol) and K3PO4( 555 mg, 2.62 mmol) in dioxane (4 mL) / water (2 mL) was added Pd(PPh3)4 (50 mg, 0.043 mmol) and heated to 100 °C for 3 h. The reaction mixture was diluted with chloroform and filtered. The filtrate was extracted with chloroform. The organic solvent was separated, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The solid obtained was purified by silica gel column chromatography to yield 160 mg of the desired product.1HNMR (400 MHz, DMSO-d6): δ 3.02 (s, 3H), 5.20 (s, 2H), 6.16 (d, J= 7.6 Hz,1H), 6.39 (s, 1H), 6.53 (d, J= 8.0 Hz,1H), 6.95 (t, J= 8.0 Hz,1H), 7.70 (d, J= 8.0 Hz,1H),7.99 (s, 1H), 8.01(d, J= 8.0 Hz,1H), 8.65 (s, 1H); ESI MS (m / z) 314.1 (M+H)+. Intermediate A13 4'-Fluoro-2'-(5-methyl-1H-1,2,3-triazol-1-yl)-[1,1'-biphenyl]-3-amine Step-1: 1-Bromo-4-fluoro-2-nitrobenzene To a stirred solution of 4-fluoro-2-nitroaniline (10 g, 64.0 mmol) in Conc. H2SO4(100 mL) was added dropwise aqueous solution of sodium nitrite (8.83 g, 128 mmol) at 0 °C and stirred for 20 min and then added suspension of cuprous bromide (18.35 g, 128 mmol) in 30% hydrobromic acid (50 mL). The reaction mixture was stirred at 0 °C for 1 h and heated to 60 °C for 3 h. The reaction mixture was poured into ice water and extracted twice with ethyl acetate. The organic layer was separated, dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain 7.12 g of the desired product.1H NMR (400 MHz, DMSO-d6): δ 7.56 (m, 1H), 7.79 (dd, J = 8.0 & 5.0 Hz, 1H), 8.12 (dd, J = 8.0 & 1.5 Hz, 1H); ESI-MS (m / z) 220.15 (M-H)+. Step-2: 2-Bromo-5-fluoroaniline To a stirred solution of 1-bromo-4-fluoro-2-nitrobenzene (7.0 g, 31.80 mmol) in methanol (70 mL) at 0 °C was added iron powder (8.8 g, 159 mmol) and dropwise conc. hydrochloric acid (15 mL) and stirred at 0 °C for 1 h. The reaction mixture was poured into ice water, basified by saturated sodium bicarbonate solution and filtered. The filtrate obtained was extracted by ethyl acetate, separated the organic layer, dried over anhydrous Na2SO4and concentrated under reduced pressure to obtain 4.12 g of the desired product.1H NMR (400 MHz, DMSO-d6): δ 5.60 (brs, Exchangeable with D2O, 2H), 6.30 (m, 1H), 7.58 (dd, J = 8.0 & 1.5 Hz, 1H), 7.45 (dd, J = 8.0 & 1.5 Hz, 1H); ESI-MS (m / z) 291.16 (M-H)+. Step-3: 2-Azido-1-bromo-4-fluorobenzene To a stirred solution of 2-bromo-5- g, 10.53 mmol) in conc. hydrochloric acid (10 mL) and water (10 mL) was added aqueous solution of sodium nitrite (1.09 g, 15.8 mmol) dropwise at 0 °C and stirred for 1.5 h. To this mixture, at 0 °C solution of sodium azide (1.02 g, 15.8 mmol) and sodium acetate (12.95 g, 158 mmol) in water (50 mL) was added and stirred at 1 h. The reaction mixture was poured in ice water, extracted by ethyl acetate, organic layer was separated, dried over anhydrous Na2SO4and concentrated under reduced pressure to obtain 2.10 g of the desired product.1H NMR (400 MHz, DMSO-d6): δ 6.75 (m, 1H), 6.92 (dd, J = 8.0 & 1.5 Hz, 1H), 7.51 (dd, J = 8.0 & 1.5 Hz, 1H); ESI-MS (m / z) 217.33 (M-H)+. Step-4: 1-(2-Bromo-5-fluorophenyl)-5-methyl-4-(trimethylsilyl)-1H-1,2,3-triazole To a stirred solution of 2-azido-1- (2.0 g, 9.25 mmol) and 1- (trimethylsilyl)-1-propyne (3.10 g, 27.77 mmol) in toluene (20 mL) was heated in a sealed tube at 110 °C for 18 h. The reaction mixture was concentrated under vacuum and the residue obtained was purified by column chromatography to obtain 1.7 g of the desired product.1H NMR (400 MHz, DMSO-d6): δ 0.34 (s, 9H), 2.18 (s, 3H), 7.52 (m, 1H), 7.73 (dd, J = 8.0 & 1.5 Hz, 1H), 7.98 (dd, J = 8.0 & 1.5 Hz, 1H); ESI-MS (m / z) 330.56 (M-H)+. Step-5: 1-(2-Bromo-5-fluorophenyl)-5-methyl-1H-1,2,3-triazole To a stirred solution of 1-(2-bromo- -5-methyl-4-(trimethylsilyl)-1H-1,2,3- triazole (1.0 g, 3.00 mmol) in THF (10 mL) was added 1M tetrabutyl ammonium fluoride (3.5 mL, 4.5 mmol) dropwise and the reaction mixture was stirred at 25 °C for 5 h. The reaction mixture was concentrated under vacuum and the residue obtained was purified by column chromatography to afford 560 mg of the desired product.1H NMR (400 MHz, CDCl3-d3): δ 2.25 (s, 3H), 7.19-7.26 (m, 2H), 7.62 (s, 1H), 7.76 (dd, J = 9.1 & 5.3 Hz, 1H); ESI-MS (m / z) 258.36 (M-H)+. Step-6: 4'-Fluoro-2'-(5-methyl-1H-1,2,3-triazol-1-yl)-[1,1'-biphenyl]-3-amine To a stirred degassed solution of 1-(2-bromo-5-fluorophenyl)-5-methyl-1H-1,2,3-triazole (200 mg, 0.781 mmol), 3-amino phenyl boronic acid (160 mg, 1.17 mmol) and K2CO3(162 mg, 1.17 mmol) in dioxane (4 mL) / water (2 mL) was added Pd(PPh3)4 (88 mg, 0.0781 mmol) and heated to 100 °C for 18 h. The reaction mixture was diluted with chloroform and filtered. The filtrate was extracted with chloroform. The organic solvent was concentrated under reduced pressure and the residue obtained was purified by silica gel column chromatography to yield 180 mg of the desired product.1H NMR (400 MHz, DMSO-d6): δ 1.85 (s, 3H), 5.09 (brs, Exchangeable with D2O, 2H), 6.97 (m, 1H), 7.48-7.76 (m, 7H); ESI-MS (m / z) 268.17 (M-H)+. Intermediate A14 4'-Fluoro-2'-(5-methyl-1H-1,2,3-triazol-4-yl)-[1,1'-biphenyl]-3-amine Step-1: 4-Fluoro-3'-nitro-[1,1'- - To a stirred degassed solution of 2- (1 g, 4.92 mmol) in Dioxane (15 mL) / water (5mL) was added 3-nitrophenyl boronic acid (1.23 g, 7.38 mmol), K3PO4(3 g, 14.76 mmol) and Pd(PPh3)4 (284 mg, 0.24 mmol) and heated to 90 °C for 3 h. The reaction mixture was diluted with ethyl acetate and filtered. The filtrate was extracted with ethyl acetate. The organic solvent was concentrated under reduced pressure and the solid obtained was purified by silica gel column chromatography to yield 1 g of the desired product.1HNMR (400 MHz, DMSO-d6): δ 7.66-7.81 (m, 4H), 7.92 (d, J= 7.6 Hz,1H), 8.28-8.34 (m,2H), 9.85 (s, 1H). Step-2: 4-Fluoro-3'-nitro-2-(2-nitroprop-1-en-1-yl)-1,1'-biphenyl To a stirred solution of 4-fluoro-3'- -2-carbaldehyde (715 mg, 2.91 mmol) in acetic acid was nitroethane (437 mg, 5.83 mmol) and ammonium acetate (244 mg, 2.91 mmol) and heated to 110 °C for 12 h. The reaction mixture was cooled to RT and diluted with water. The solid precipitated was filtered, dried and used for next step without further purification. Step-3: 4-(4-Fluoro-3'-nitro-[1,1'-biphenyl]-2-yl)-5-methyl-1H-1,2,3-triazole To a stirred solution of 4-fluoro-3'- 1-en-1-yl)-1,1'-biphenyl (400 mg, 1.32 mmol) in DMSO was added sodium azide (129 mg, 1.98 mmol) and heated to 90 °C for 12 h. The reaction mixture was cooled to RT and diluted with water. The solid precipitated was filtered, dried and the residue obtained was purified with silica gel column chromatography to obtain 230 mg of the desired product.1HNMR (400 MHz, DMSO-d6): δ 1.76 (s, 3H), 7.38- 7.67 (m, 5H), 7.90 (s, 1H), 8.15 (d, J= 7.6 Hz,1H), 14.68 (m,1H). Step-4: 4'-Fluoro-2'-(5-methyl-1H-1,2,3-triazol-4-yl)-[1,1'-biphenyl]-3-amine To a stirred solution of 4-(4-fluoro-3'-nitro-[1,1'-biphenyl]-2-yl)-5-methyl-2H-1,2,3-triazole (230 mg, 0.771 mmol) in methanol was added 10% Pd / C (40 mg) and stirred under hydrogen atmosphere at RT for 24 h. The reaction mixture was filtered, washed with methanol. The filtrate obtained was concentrated under reduced pressure and the residue obtained was purified by silica gel column chromatography to obtain 200 mg of the desired product.1HNMR (400 MHz, DMSO-d6): δ 1.61 (s, 3H), 5.03 (s, 2H), 6.16 (d, J=6.0 Hz, 1H), 6.35 (s, 1H), 6.44 (d, J= 8.0 Hz,1H), 6.89 (t, J= 7.6 Hz,1H), 7.24-7.43 (m, 3H), 14.53 (brs,1H). Intermediate A15 6-(4-Fluoro-2-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-2-methylimidazo[1,2-a]pyridin-8- amine Step-1: 6-Bromo-2-methylimidazo[1,2-a] To a stirred solution of 5- (2.0 g, 10.63 mmol) and chloroacetone (2.95 g, 31.91mmol) in ethanol was refluxed for 18 h. The reaction mixture was concentrated, quenched with sat. sodium bicarbonate and extracted thrice with ethyl acetate. The organic layer was separated, concentrated under vacuum and purified by column chromatography to obtain 1.2 g of the desired product.1H NMR (400 MHz, DMSO-d6) ^ 2.29 (s, 3H), 5.90 (bs, 2H), 6.27(d, J=2.0Hz, 1H), 7.51(d, J = 0.4 Hz, 1H), 7.96 (d, J=1.6Hz,1H); ESI-MS (m / z) 226 (M+H)+. Step-2: (8-Amino-2-methylimidazo[1,2-a]pyridin-6-yl)boronic acid To a stirred solution of 6-bromo-2-methylimidazo[1,2-a]pyridin-8-amine (200 mg, 0.88 mmol) in degassed dioxane (10 mL) were added Bis(pinacolato)diboron (448 mg, 1.76- mmol), KOAc (260 mg, 2.65mmol) and Pd(dppf)Cl2.DCM (36 mg, 0.04 mmol). The resulting reaction was stirred at 90 °C for 18 h in a sealed tube. The reaction mixture was filtered and the filtrate obtained was concentrated to obtain 180 mg of the desired product. ESI-MS (m / z) 192 (M+H)+. Step-3: 6-(4-Fluoro-2-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-2-methylimid azo[1,2- a]pyridin-8-amine To a stirred solution of 3-(2-bromo-5-fluorophenyl)-4-methyl-4H-1,2,4-triazole (224 mg , 0.875 mmol) and (8-amino-2-methylimidazo[1,2-a]pyridin-6-yl)boronic acid (168 mg, 0.875 mmol) in a degassed solvent mixture of dioxane (6 mL) and water (1 mL) was added K2CO3 (362 mg, 2.62 mmol), Pd(PPh3)4 (101 mg, 0.028 mmol) and heated to 90 °C for 18 h. The reaction mixture was quenched with water and extracted thrice with ethyl acetate. The organic layer was separated, concentrated and purified using column chromatography to obtain 136 mg of the desired product.1H NMR (400 MHz, DMSO-d6) ^ 2.27 (s, 3H), 3.19(s, 3H), 5.57(s, 2H), 5.93(d,J=1.2Hz, 1H), 7.41-7.46(m, 3H), 7.50-7.55(m, 1H), 7.61-7.63(m, 1H), 8.43(s, 1H), ESI-MS (m / z) 323 (M+H)+. Intermediate A16 6-Cyclopropyl-4-(4-fluoro-2-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl) pyridin-2-amine Step-1: 4-Chloro-6-cyclopropylpyridin-2- To a stirred solution of 4,6- (3.0 g, 18.40 mmol) in toluene (61 mL) and water (30 mL) was degassed using Nitrogen for 15 min and then added cyclopropyl boronic acid (1.74 g, 20.24 mmol), Na2CO3(5.85 g, 55.2 mmol), Pd(PPh3)4(2.12g, 1.84 mmol). The resulting mixture was stirred at reflux temperature for 18 h. The reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was separated, concentrated and purified by column chromatography followed by Supercritical fluid chromatography (SFC) to obtain 310 mg of the desired product.1H NMR (400 MHz, DMSO- d6) ^ 0.89-0.97 (m, 4H), 1.82-1.89 (m, 1H), 4.39 (s, 2H),6.28 (d, J=1.2Hz, 1H), 6.51(J=1.6Hz, 1H) ESI-MS (m / z) 169 (M+H)+. Step-2: (2-Amino-6-cyclopropylpyridin-4-yl)boronic acid To a stirred degassed solution of 4- 2-amine (50 mg, 0.295 mmol) in dioxane (5 mL) was added Bis(pinacolato)diboron (150mg, 0.59 mmol), KOAc (87mg, 0.88 mmol), PCy3(6.0 mg, 0.022 mmol) and Pd2(dba)3(14mg, 0.014 mmol). The resulting reaction was stirred for 30 min at 120 °C. The reaction mixture was filtered and the filtrate obtained was concentrated to obtain 110 mg of the desired product. ESI-MS (m / z) 179 (M+H)+. Step-3: 6-Cyclopropyl-4-(4-fluoro-2-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl) pyridin-2- amine To a stirred degassed solution of 3-(2-bromo-5-fluorophenyl)-4-methyl-4H-1,2,4-triazole (75 mg, 0.292 mmole) and 2-amino-6-cyclopropylpyridin-4-yl)boronic acid (52 mg, 0.292 mmol) in a solvent mixture of dioxane (5 mL) and water (1 mL) was added K2CO3(121 mg, 0.878 mmol) and Pd(PPh3)4(34mg, 0.029 mmol). The resulting reaction was stirred in a sealed tube at 100 °C for 18 h. The reaction mixture was quenched with water and extracted thrice with ethyl acetate. The organic layer was separated, concentrated and purified by column chromatography to obtain 58 mg of the desired product.1H NMR (400 MHz, DMSO-d6) ^ 0.67-0.71 (m, 2H), 0.75-0.79(m, 2H), 1.71-1.75(m, 1H), 3.17(s,3 H), 5.79(s, 2H), 5.91(d, J=1.6Hz, 1H),6.01(d, J=1.6Hz, 1H), 7.41-7.44(m, 1H), 7.50-7.55(m, 1H), 7.57-7.61(m, 1H), 8.48(s, 1H), ESI-MS (m / z) 310 (M+H)+. Intermediate A17 3-(1-Methyl-4-(4-methyl-4H-1,2,4-triazol-3-yl)-1H-pyrazol-3-yl)aniline Step-1: Ethyl 3-bromo-1H-pyrazole-4- To a stirred solution of ethyl 3-amino-4-pyrazole carboxylate (10 g, 64.4 mmol) in acetonitrile (200 mL) at 0 °C was added Copper(II)bromide (14.4 g, 64.4 mmol) followed by isoamyl nitrite (23.2 mL, 173.97 mmol) dropwise. The resultant reaction suspension was warmed to RT and heated at 50 °C for 16 h. The reaction mixture was cooled to RT, quenched with aq. 1N HCl solution (500 mL) at 0 °C and extracted twice with ethyl acetate. The combined organic layer was washed with brine solution, dried over anhydrous Na2SO4, concentrated and purified by column chromatography to obtain 8.65 g of the desired product.1H NMR (400 MHz, DMSO-d6): ^ 1.40 (t, J=7.2 Hz, 3H), 4.36 (q, J=7.2 Hz, 2H), 8.11 (s, 1H), 11.69 (bs, 1H); ESI-MS (m / z) 220.0 (M+ H)+. Step-2: Ethyl 3-bromo-1-methyl-1H-pyrazole-4-carboxylate To a stirred solution of ethyl 3- 4-carboxylate (8.6 g, 39.26 mmol) in anhydrous THF (300 mL) at 0 °C was added NaH (60% suspension in mineral oil) (2.36 g, 58.89 mmol) and stirred for 30 min. To this reaction mixture was added methyl iodide (11.05 ml, 176.7 mmol) dropwise and temperature raised to RT and stirred for 16 h. The reaction mixture was quenched with saturated ammonium chloride solution (200 mL) and extracted thrice with ethyl acetate. The combined organic layer was washed with brine, dried over anhydrous Na2SO4, concentrated and purified by column chromatography using Acetone / Petroleum ether as eluent to obtain 4.34 g of the desired product.1H NMR (400 MHz, DMSO-d6): ^ 1.27 (t, J=7.2 Hz, 3H), 3.86 (s, 3H), 4.21 (q, J=7.2 Hz, 2H), 8.36 (s, 1H); ESI- MS (m / z) 234.9 (M+2H)+. Step-3: Ethyl 1-methyl-3-(3-nitrophenyl)-1H-pyrazole-4-carboxylate To a stirred solution of ethyl 3- 4-carboxylate (1.5 g, 6.44 mmol) and 3-nitrophenyl boronic acid (1.29 g, 7.72 mmol) in degassed 1,4-Dioxane / H2O (4:1, 50 mL) were added K2CO3 (2.67 g, 19.31 mmol) and Pd(dppf)Cl2.DCM (525 mg, 0.644 mmol). The reaction mixture was heated at 100 °C for 4 h. The reaction mixture was cooled to RT, diluted with ethyl acetate and washed with water, brine, dried over anhydrous Na2SO4, concentrated and purified by column chromatography using 30% to 40% ethyl acetate / Petroleum ether as eluent to obtain 1.55 g of the desired product.1H NMR (400 MHz, DMSO-d6): ^ 1.23 (t, J=7.2 Hz, 3H), 3.96 (s, 3H), 4.20 (q, J=7.2 Hz, 2H), 7.73 (t, J= 8 Hz, 1H), 8.22 – 8.28 (m, 2H), 8.47 (s, 1H), 8.65 (t, J=2 Hz, 1H),; ESI-MS (m / z) = 276.1 (M+ H)+. Step-4: 1-Methyl-3-(3-nitrophenyl)-1H-pyrazole-4-carboxylic acid To a stirred solution of ethyl 1- -1H-pyrazole-4-carboxylate (1.53 g, 5.56 mmol) in THF / H2O (5:1, 25 mL) was added LiOH. H2O (700 mg, 16.67 mmol) and heated at 60 °C for 16 h. The reaction mixture was cooled to RT and concentrated under vacuum. The residue thus obtained was diluted with 1N NaOH solution (50 mL) and washed twice with ethyl acetate and the aqueous layer was acidified under cooling at 0 °C with 1N HCl solution (pH-3). The solid precipitated was filtered, washed with cold water and dried under vacuum to obtain 1.2 g of the desired product.1H NMR (400 MHz, DMSO-d6): ^ 3.95 (s, 3H), 7.72 (t, J= 8 Hz, 1H), 8.23 – 8.29 (m, 2H), 8.4 (s, 1H), 8.69 (s, 1H), 12.50( bs, 1H); ESI-MS (m / z) 248.1 (M+ H)+. Step-5: N-Methyl-2-(1-methyl-3-(3-nitrophenyl)-1H-pyrazole-4-carbonyl) hydrazine-1- carbothioamide To a stirred solution of 1-methyl- - 4-carboxylic acid (1.1 g, 4.45 mmol) in DMF (15 ml) at 0 °C was added HATU (2.03 g, 5.34 mmol) and stirred for 30 min and 4-methyl-3-thiosemicarbazide (608 mg, 5.78 mmol) and DIPEA (2.3 ml, 13.35 mmol) were added and stirred at RT for 16 h. The reaction mixture was concentrated under vacuum to obtain 1.4 g of the desired product. ESI-MS (m / z) 334.8 (M+H)+. Step-6: 4-Methyl-5-(1-methyl-3-(3-nitrophenyl)-1H-pyrazol-4-yl)-4H-1,2,4-triazole-3-thiol To a stirred solution of N-methyl- -1H-pyrazole-4-carbonyl) hydrazine-1-carbothioamide (1.46 g, 4.37 mmol) in aqueous 1N NaOH solution (90 mL) was stirred at RT for 16 h. The reaction mixture was washed twice with diethyl ether. The aqueous layer was acidified with 1N HCl solution to pH-4 and extracted thrice with ethyl acetate. The combined organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue obtained was triturated with diethyl ether and the solid precipitated was filtered to obtain 806 mg of the desired product.1H NMR (400 MHz, DMSO-d6): ^ 3.34 (s, 3H), 4.02 (s, 3H), 7.7 (t, J= 8 Hz, 1H), 7.93 (t, J= 6.8 Hz, 1H), 8.19 - 8.23( m, 1H), 8.40 – 8.42(m, 2H), 13.89(bs, 1H); ESI-MS (m / z) = 317.3 (M+ H)+. Step-7: 4-Methyl-3-(1-methyl-3-(3-nitrophenyl)-1H-pyrazol-4-yl)-4H-1,2,4-triazole To a stirred solution of 4-methyl-5- -1H-pyrazol-4-yl)-4H-1,2,4- triazole-3-thiol (800 mg, 2.53 mmol) in AcOH (2.18 ml, 37.93 mmol) in DCM (75 mL) at 0 °C was added aq.30% H2O2 solution (0.78 ml, 7.59 mmol) dropise. The resultant mixture was stirred at 0 °C for 2 h. The reaction mixture was quenched saturated aq. sodium bicarbonate solution (50 mL) and extracted twice with DCM (2 x 100 mL). The combined organic layer was washed with water, brine, dried over anhydrous Na2SO4, concentrated and purified by column chromatography using MeOH / DCM as eluent to obtain 508 mg of the desired product.1H NMR (400 MHz, DMSO-d6): ^ 3.34 (s, 3H), 4.02 (s, 3H), 7.66 (t, J= 8 Hz, 1H), 7.97-7.99 (m, 1H), 8.17 - 8.19( m, 1H), 8.29( s, 1H), 8.43(d, J= 6 Hz, 1H), 8.61(s, 1H); ESI-MS (m / z) 285.1(M+ H)+. Step-8: 3-(1-Methyl-4-(4-methyl-4H-1,2,4-triazol-3-yl)-1H-pyrazol-3-yl)aniline To a stirred suspension of 4-methyl-3-(1-methyl-3-(3-nitrophenyl)-1H-pyrazol-4-yl)-4H- 1,2,4-triazole (500 mg, 1.76 mmol) in MeOH (40 mL) was added 10% Pd-C (50 % wet, 100 mg) portion wise and stirred under hydrogen atmosphere at RT for 5 h. The reaction mixture was diluted with methanol (100 mL) and filtered. The filtrate obtained was concentrated and purified by column chromatography using MeOH / DCM as eluent to obtain 335 mg of the desired product.1H NMR (400 MHz, DMSO-d6): ^ 3.23 (s, 3H), 3.94 (s, 3H), 5.09 (bs, 2H), 6.32-6.34(m, 1H), 6.48 - 6.51(m, 1H), 6.75 (t, J= 7.6 Hz, 1H), 6.90 – 6.94 (m, 1H), 8.05( s, 1H), 8.52( s, 1H); ESI-MS (m / z) 255.1(M+ H)+. Intermediate A18 6-(4-Fluoro-2-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)quinolin-8-amine Step-1: 6-Bromo-8-nitroquinoline To a stirred solution of 4-bromo-2-nitroaniline (5.0 g, 23.04 mmol) in 75% aq. H2SO4 (15 mL) were added glycerol (2.4 g, 27.6 mmol) and NaI (100 mg) at RT. The reaction mixture was stirred at 140 °C for 3 h. The reaction mixture was quenched with ice water and neutralized with aq. NaOH (pH ~ 7-8). The aqueous layer was extracted twice with DCM. The organic layer was separated, dried over anhydrous Na2SO4 and concentrated under vacuum. The residue obtained was purified by silica gel column chromatography to yield 3.2 g of the desired product.1H NMR (400 MHz, CDCl3-d3) ^ 7.79 (t, J = 4.0 Hz, 1H), 8.53-862 (m, 3H), 9.05- 9.07 (m, 1H). ESI-MS (m / z) 254.5 (M+H)+. Step-2: 6-Bromoquinolin-8-amine To a stirred solution of 6-bromo-8- g,5.78 mmol) in MeOH / AcOH / H2O (2:2:1) (50 mL) was added Fe powder (3.3 g,52.28 mmol). The reaction mixture was refluxed for 3 h. The reaction mixture was cooled to RT and filtered, the filtrate was diluted with sodium bicarbonate solution and extracted twice with DCM. The organic layer was separated, dried over anhydrous Na2SO4 and concentrated. The residue obtained was purified by silica gel column chromatography to yield 1.3 g of the desired product.1HNMR (400 MHz, CDCl3): δ 6.25 (s, 2H), 6.94 (s, 1H), 7.26 (s, 1H), 7.49-7.52 (m, 1H),8.14-8.16 (m, 1H), 8.73 – 8.74 (m, 1H), ESI-MS (m / z) 224.4 (M+H)+. Step-3: 6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)quinolin-8-amine To a stirred solution of 6- mg, 3.81 mmol) and 4,4,4′,4′,5,5,5′,5′- Octamethyl-2,2′-bi-1,3,2-dioxaborolane (1.93 g,7.62 mmol) in dioxane (30 mL) was degassed with nitrogen gas for 10 min. To reaction mixture were added KOAc (1.40 g,15.24 mmol) and Pd(dppf)cl2 DCM complex (155 mg,0.19 mmol). The reaction mixture was refluxed for 16 h. The reaction mixture was cooled to RT and diluted with water and extracted twice with ethyl acetate. The organic layer was separated, dried over anhydrous Na2SO4 and concentrated. The residue obtained was purified by silica gel column chromatography to yield 900 mg of the desired product.1HNMR (400 MHz, DMSO-d6): δ 1.32 (s, 12H), 5.88 (s, 2H), 7.69 (d, J = 1.2 Hz, 1H),7.46-7.49 (m, 2H), 8.25-8.28 (m, 1H), 8.76-877 (m, 1H), ESI-MS (m / z) 271.2 (M+H)+. Step-4: 6-(4-Fluoro-2-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)quinolin-8-amine To a stirred solution of 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinolin-8-amine (367 mg,2.36 mmol) and 3-(2-bromo-5-fluorophenyl)-4-methyl-4H-1,2,4-triazole (300 mg,1.18 mmol) in dioxane (9.0 mL) and water (3.0 mL) was degassed with nitrogen gas for 10 min. To the reaction mixture were added K2CO3(651 mg,4.72 mmol) and Pd(PPh3)4(68 mg,0.059 mmol) and stirred at 130 °C in a sealed tube for 16 h. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was dried over anhydrous Na2SO4 and concentrated. The residue obtained was purified by flash column chromatography to yield 220 mg of the desired compound.1H NMR (400 MHz, DMSO-d6) ^ 3.07 (s, 3H), 5.97 (s, 2H), 6.11 (s, 1H), 6.75 (s, 1H), 7.42-7.47 (m, 2H), 7.53-7.57 (m, 1H), 7.67-7.70 (m, 1H), 8.04-8.06 (m, 1H), 8.37 (s, 1H), 8.70-8.71 (m, 1H); ESI-MS (m / z) 320.2 (M+H)+. Intermediate A19 6-Bromo-1-methyl-1H-benzo[d]imidazol-4-amine Step-1: Methyl 2-amino-5-bromo-3- To a stirred solution of methyl 2- (0.5 g, 2.55 mmol) in acetic acid (8 mL) was added bromine (0.13 mL, 2.55 mmol) at 0 °C and stirred at RT for 1 h. The reaction mixture was poured in ice cold water and stirred for 30 min. The solid thus obtained was filtered and dried under vaccum to obtain 645 mg of the desired product.1H NMR (400 MHz, DMSO-d6) ^ 3.95 (s, 3H), 4.79 (bs, 2H), 8.34 (t, J=2.8 Hz, 1H), 8.52 (t, J= 2.4 Hz, 1H). Step-2: Methyl 2,3-diamino-5-bromobenzoate To a stirred solution of methyl 2-amino-5-bromo-3-nitrobenzoate (2.0 g, 7.27 mmol) in a solvent mixture of THF / EtOH / H2O (1:1:0.4, 100 mL) was added iron powder (2.03 g, 36.4 mmol) and ammonium chloride (5.83 g, 109.1 mmol) and refluxed for 3 h. The reaction mixture was diluted with ethyl acetate and filtered. The filtrate obtained was concentrated and the obtained solid was diluted with ethyl acetate and further washed with water. The organic layer was separated, dried over anhydrous Na2SO4and concentrated under reduced pressure to yield 1.51 g of the desired product.1H NMR (400 MHz, DMSO-d6) ^ 3.77 (s, 3H), 5.17 (bs, 2H), 6.37 (bs, 2H), 6.80 (d, J=2.4 Hz, 1H), 7.14 (d, J=2 Hz,1H); ESI-MS (m / z) 246.9 (M+ H)+. Step-3: Methyl 6-bromo-1H-benzo[d]imidazole-4-carboxylate To a stirred solution of methyl (1.5 g, 6.100 mmol) in formic acid (15 mL) was heated in a sealed tube at 90 °C for 18 h. The reaction mixture was concentrated under reduced pressure and the crude obtained was neutralized with sat. sodium bicarbonate solution and stirred for 30 min. The obtained solid was filtered and dried to yield 1.1 g of the desired product.1H NMR (400 MHz, DMSO-d6) ^ 3.96 (s, 3H), 7.90 (d, J=1.6 Hz, 1H), 8.19(d, J= 1.6 Hz, 1H), 8.39 (s, 1H), 12.80(bs, 1H); ESI-MS (m / z) 257 (M+2H)+. Step-4: Methyl 6-bromo-1-methyl-1H-benzo[d]imidazole-4-carboxylate To a stirred solution of methyl 6- 4-carboxylate (1.07 g, 4.200 mmol) in THF (15 mL) was added NaH (184 mg, 4.60 mmol) at 0 °C under nitrogen atmosphere and stirred at RT for 30 min. To the reaction mixture was added methyl iodide (315 µl, 5.00 mmol) drop wise to the reaction mixture at 0 °C and stirred at RT for 16 h. The reaction mixture was quenched with aq. sat. ammonium chloride and extracted with ethyl acetate. The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue obtained was purified by silica gel column chromatography to obtain 846 mg of the desired product.1H NMR (400 MHz, DMSO-d6) ^ 3.88 (s, 3H), 3.90(s, 3H), 7.84(d, J=2 Hz, 1H), 8.17(d, J= 2 Hz, 1H), 8.37(s, 1H); ESI-MS (m / z) 271.1 (M+ 2H)+. Step-5: 6-Bromo-1-methyl-1H-benzo[d]imidazole-4-carboxylic acid To a stirred solution of methyl 6- benzo[d]imidazole-4-carboxylate (400 mg, 1.486 mmol) in MeOH (6 mL) and THF (6 mL) was added LiOH.H2O (312 mg, 7.432 mmol) and water (3 mL) and reaction was stirred at RT for 18 h. The reaction mixture was concentrated and acidified with citric acid solution (pH=4-5) and stirred for 30 min and extracted with 15% MeOH / DCM. The organic layer was dried over anhydrous Na2SO4and concentrated under reduced pressure to obtain 250 mg of the desired product.1H NMR (400 MHz, DMSO-d6) ^ 3.90 (s, 3H), 7.85(d, J=2 Hz, 1H), 8.19(d, J= 2 Hz, 1H), 8.45(s, 1H), 12.30(bs, 1H); ESI-MS (m / z) 254.9 (M+ H)+. Step-6: 6-Bromo-1-methyl-1H-benzo[d]imidazol-4-amine To a stirred solution of 6-bromo-1-methyl-1H-benzo[d]imidazole-4-carboxylic acid (500 mg, 1.960 mmol) in DMF (5 mL) was added TEA (0.409 mL, 2.940 mmol) and diphenyl phosphoryl azide (809.2 mg, 2.940 mmol) at 0 °C and stirred at RT for 4 h. To the reaction mixture was added water (5 mL) and stirred at 100 °C for 1 h. The reaction mixture was diluted with water and extracted thrice with ethyl acetate. The organic layer was separated, dried over anhydrous Na2SO4and concentrated under reduced pressure. The residue obtained was purified by flash chromatography to obtain 309 mg of the desired product.1H NMR (400 MHz, DMSO-d6) ^ 3.72 (s, 3H), 5.56 (bs, 2H), 6.50 (d, J=1.6 Hz, 1H), 6.90 (d, J= 2 Hz, 1H), 7.95(s, 1H); ESI-MS (m / z) 226 (M+H)+. Intermediate B1 2-Oxo-1-(2,2,2-trifluoroethyl)-5-vinyl-1,2-dihydropyridine-3-carboxylic acid Step-1: Methyl 5-bromo-2-oxo-1, 2- carboxylate To a stirred solution of 5-Bromo-2-hydroxy nicotinic acid (5.0 g, 35.94 mmol) in dry methanol (100 mL) was added Conc. H2SO4(1 mL) and refluxed for 18 h. The reaction mixture was cooled to RT and concentrated under reduced pressure. The residue obtained was basified with saturated sodium bicarbonate solution and stirred for 30 min. The solid obtained was filtered and dried under vacuum to obtain 4.2 g of the desired product.1H NMR (400 MHz, DMSO- d6) ^ 3.75 (s, 3H), 7.99 (d, J = 2.8 Hz, 1H), 8.08 (d, J = 2.8 Hz, 1H), 12.41 (brs, 1H); ESI-MS (m / z) 233 (M+2H)+. Step-2: Methyl 5-bromo-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3-carboxylate To a stirred solution of methyl 5- 3-carboxylate (5.2 gm, 22.413 mmol) in DMF (80 mL) was added cesium carbonate (10.9 g, 33.620 mmol) and stirred for 30 min at RT. To this mixture was added 2, 2, 2-Trifluoro ethyltrifluoromethane sulfate (7.8 g, 33.62 mmol) and heated to 70 °C for overnight. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was dried over anhydrous Na2SO4and concentrated under reduced pressure. The residue obtained was purified by silica gel chromatography to yield 2.9 g of the desired compound.1H NMR (400 MHz, DMSO-d6) ^ 3.77 (s, 3H), 4.87 (q, J= 9.2 Hz, 2H), 8.14 (d, J = 2.4 Hz, 1H), 8.36 (d, J = 2.4 Hz, 1H); ESI- MS (m / z) 315 (M+2H)+. Step-3: Methyl 2-oxo-1-(2,2,2-trifluoroethyl)-5-vinyl-1,2-dihydropyridine-3-carboxylate To a stirred solution of methyl 5- trifluoroethyl)-1,2-dihydropyridine-3- carboxylate (1.5 g, 4.76 mmol) and potassium vinyl trifluoroborate (1.91 g, 14.28 mmol) in a mixture of toluene (50 mL) / water (15 mL) was degassed for 15 min. To this reaction mixture were added K3PO4(4 g, 19.04 mmol), Pd(dppf)Cl2.DCM (390 mg, 0.476 mmol) and heated to 100 °C for 5 h. The reaction mixture was diluted with water and extracted twice with ethyl acetate. The organic layer was separated, dried over anhydrous Na2SO4 and concentrated under vacuum. The residue obtained was purified by silica gel column chromatography to yield 1.09 g of the desired compound.1H NMR (400 MHz, DMSO-d6) ^ 3.78 (s, 3H), 4.90 (q, J = 9.2 Hz, 2H), 5.22 (d, J= 11.2 Hz, 1H), 5.68 (d, J = 17.6 Hz, 1H), 6.45- 6.6 (m, 1H), 8.103 (d, J = 2Hz, 1H), 8.33 (d, J = 2.8 Hz, 1H); ESI-MS (m / z) 262.3 (M+H)+. Step-4: 2-Oxo-1-(2,2,2-trifluoroethyl)-5-vinyl-1,2-dihydropyridine-3-carboxylic acid To a stirred solution of methyl 2-oxo-1-(2,2,2-trifluoroethyl)-5-vinyl-1,2-dihydropyridine-3- carboxylate (1 g, 3.831 mmol) in THF / MeOH (40 mL, 1:1) was added aqueous LiOH (481 mg, 11.49 mmol) and stirred at RT for overnight. The reaction mixture was concentrated and the residue obtained was diluted with water and acidified using 1N HCl. The solid precipitated was filtered and dried to yield 809 mg of the desired product.1H NMR (400 MHz, DMSO-d6) ^ 5.01 (q, J = 9.2 Hz, 2H), 5.28 (d, J = 11.2 Hz, 1H), 5.76 (d, J = 17.6 Hz, 1H), 6.50- 6.70 (m, 1H), 8.19 (s, 1H), 8.53 (d, J = 2.4 Hz, 1H), 13.86 (brs, 1H); ESI-MS (m / z) 248.2 (M+H)+. Intermediate B2 1-(Cyclopropylmethyl)-2-oxo-5-vinyl-1,2-dihydropyridine-3-carboxylic acid Step-1: Methyl 5-bromo-1- - 1,2-dihydropyridine-3-carboxylate To a stirred solution of methyl 5-bromo- 3-carboxylate (10 g, 43.10 mmol) in DMF (100 mL) was added potassium carbonate (8.9 g, 64.65 mmol) and stirred at RT for 30 min. To this mixture was added cyclopropyl methyl bromide (6.28 ml, 64.65 mmol) and heated to 70 °C for overnight. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was dried over anhydrous Na2SO4and concentrated. The residue obtained was purified by silica gel chromatography to yield 7.1 g of the desired product.1H NMR (400 MHz, DMSO-d6) ^ 0.35- 0.45 (m, 2H), 0.45- 0.55 (m, 2H), 1.18- 1.35 (m, 1H), 3.75 (s, 3H), 3.77 (d, J = 9.6 Hz, 2H), 8.05 (d, J = 2.8 Hz, 1H), 8.38 (d, J = 2.8 Hz, 1H); ESI-MS (m / z) 287 (M+2H)+. Step-2: Methyl 1-(cyclopropylmethyl)-2-oxo-5-vinyl-1,2-dihydropyridine-3-carboxylate To a stirred solution of Methyl 5-bromo-1-(cyclopropylmethyl)-2-oxo-1,2-dihydropyridine-3- carboxylate (7.1 g, 24.82 mmol) and potassium vinyl trifluoroborate (9.97 g, 74.47 mmol) in a solvent mixture of toluene (150 mL) / water (40 mL) was degassed for 15 min. To this reaction mixture were added K3PO4 (21 g, 99.28 mmol), Pd(dppf)Cl2.DCM (2 g, 2.482 mmol) and heated to 100 °C for 5 h. The reaction mixture was diluted with water and extracted twice with ethyl acetate. The organic layer was separated, dried over anhydrous Na2SO4 and concentrated under vacuum. The residue obtained was purified by silica gel column chromatography to yield 3.8 g of the desired product.1H NMR (400 MHz, DMSO-d6) ^ 0.40 - 0.44 (m, 2H), 0.63 - 0.67 (m, 2H), 1.27 - 1.32 (m, 1H), 3.86 (d, J = 7.2 Hz, 2H), 3.94 (s, 3H), 5.11 (d, J = 10.8 Hz, 1H), 5.57 (d, J = 17.2 Hz, 1H), 6.41 – 6.45 (m, 1H), 7.58 (s, 1H), 8.38 (d, 1H); ESI-MS (m / z) 224 (M+H)+. Step-3: 1-(Cyclopropylmethyl)-2-oxo-5-vinyl-1,2-dihydropyridine-3-carboxylic acid To a stirred solution of Methyl 1-(cyclopropylmethyl)-2-oxo-5-vinyl-1,2-dihydropyridine-3- carboxylate (3.8 g, 16.30 mmol) in THF (40 ml) and MeOH (40 ml) was added aqueous LiOH (3.4 g, 81.54 mmol) (solution in 20 ml water) and stirred at RT for overnight. The reaction mixture was concentrated and the residue obtained was diluted with water and acidified using 1N HCl. The solid precipitated was filtered and dried to yield 3.1 g of the desired product.1H NMR (400 MHz, DMSO-d6) ^ 0.40 – 0.60 (m, 4H), 1.20 – 1.40 (m, 1H), 3.96 (d, J= 7.6 Hz, 2H), 5.20- 5.40 (m, 1H), 5.50- 5.95 (m, 1H), 6.55- 6.70 (m, 1H), 8.45 (d, J= 2.4 Hz, 1H), 8.58 (d, J= 2.4 Hz, 1H), 14.61 (s, 1H); ESI-MS (m / z) 220.1 (M+H)+. The analytical data of the intermediate prepared by following the procedure described above are given in below Table 2. Table 2: Structure, Name and analytical data of Intermediate B3. Intermediate Structure IUPAC Name and Analytical data No. 1H NMR (400 MHz, DMSO-d6) ^ 3.66 (s, 3H), 5.29 (d, J = 11.2 Hz,1H), B3 5.80 (d, J = 17.6 Hz,1H), 6.61 (dd, J1 1-Methyl-2-oxo-5-vinyl- = 11.2 Hz, J2= 17.6 Hz, 1H), 8.42 (d, 1,2-dihydro pyridine-3- J = 2.8Hz,1H), 8.54 (d, J = 2.4 carboxylic acid Hz,1H), 14.62 (s, 1H). ESI-MS (m / z) 180.1 (M+H)+Intermediate B4 1-Cyclopropyl-2-oxo-5-vinyl-1,2-dihydropyridine-3-carboxylic acid Step-1: Methyl 5-bromo-1- 3-carboxylate To a stirred solution of methyl 5- 3-carboxylate (2.0 g, 8.62 mmol), cyclopropyl boronic acid (1.5 g, 17.24 mmol), Bipyridyl (1.4 g, 8.62 mmol), Na2CO3 (1.82 g, 17.24 mmol) and Cu(OAc)2 (1.6 g, 8.62 mmol) in 1,2 dichloroethane was degassed using oxygen. The reaction mixture was heated to 70 °C for 2-3 h under oxygen atmosphere. The reaction mixture was cooled to RT, then diluted with chloroform and filtered. The filtrate was concentrated and the crude obtained was purified by column chromatography to obtain 895 mg of the desired product.1H NMR (400 MHz, DMSO-d6) ^ 0.92-0.95 (m, 2H), 0.97- 0.99(m, 2H), 3.31-3.35(m, 1H), 3.75 (s, 3H), 8.02 (d, J=2.8 Hz, 1H), 8.09(d, J=2.8 Hz, 1H); ESI-MS (m / z) 272.0 (M+H)+. Step-2: Methyl 1-cyclopropyl-2-oxo-5-vinyl-1,2-dihydropyridine-3-carboxylate To a stirred solution of methyl 5-bromo-1-cyclopropyl-2-oxo-1,2-dihydropyridine-3- carboxylate (100 mg, 0.367 mmol) and potassium vinyl trifluoroborate (148 mg, 1.10 mmol) in a solvent mixture of dioxane (3 mL) / water (1 mL) was degassed for 15 min. To this reaction mixture were added K3PO4 (233 mg, 1.10 mmol), Pd(dppf)Cl2.DCM (30 mg, 0.03 mmol) and heated to 100 °C for 3 h. The reaction mixture was diluted with water and extracted twice with ethyl acetate. The organic layer was separated, dried over anhydrous Na2SO4 and concentrated under vacuum. The residue obtained was purified by silica gel column chromatography to yield 71 mg of the desired product.1H NMR (400 MHz, DMSO-d6) ^ 0.88-0.92 (m, 2H), 0.99- 1.04(m, 2H), 3.36-3.38(m, 1H), 3.76 (s, 3H), 5.12 (d, J=11.2 Hz, 1H), 5.61(d, J=12.8 Hz, 1H),6.52-6.59(m, 1H), 7.91 (d, J=2.8 Hz, 1H),8.22(d, J=2.8 Hz, 1H); ESI-MS (m / z) 220.1 (M+H)+. Step-3: 1-Cyclopropyl-2-oxo-5-vinyl-1,2-dihydropyridine-3-carboxylic acid To a stirred solution of methyl 1-cyclopropyl-2-oxo-5-vinyl-1,2-dihydropyridine-3- carboxylate (400 mg, 1.82 mmol) in THF (4 mL) and methanol (3 mL) was added aqueous LiOH (384 mg, 9.13 mmol) and was stirred at RT for 5 h. The reaction mixture was concentrated, cooled to 0 °C and acidified with 1N HCl. The precipitated solid was filtered and dried under vacuum to obtain 310 mg of the desired product.1H NMR (400 MHz, DMSO-d6) ^ 1.07-1.10 (m, 4H), 3.50-3.56 (m, 1H), 5.27 (d, J=11.2 Hz, 1H), 5.82(d, J=17.4 Hz, 1H), 6.61-6.69(m, 1H), 8.20 (d, J=2.0 Hz, 1H), 8.57(d, J=2.4 Hz, 1H), 11.65 (s, 1H); ESI-MS (m / z) 206.2 (M+H)+. EXAMPLES Method-A Example-1 (S)-N-(4'-cyano-2'-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-3-yl) -5-((3- methylpiperidin-1-yl)methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3- carboxamide Step-1: N-(4'-cyano-2'-(4- - biphenyl]-3-yl)-2-oxo-1-(2,2,2- trifluoroethyl)-5-vinyl-1,2-dihydropyridine-3-carboxamide To a stirred solution of 2-oxo-1-(2,2,2-trifluoroethyl)-5-vinyl-1,2-dihydropyridine-3- carboxylic acid (Intermediate B1) (194 mg, 0.78 mmol) in DMF (15 mL) was added HATU (370 mg, 0.975 mmol) followed by DIPEA (251 mg, 1.95 mmol) and stirred at RT for 20 min. To this mixture was added 3'-amino-2-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-4- carbonitrile (Intermediate A12) (180 mg, 0.65 mmol) and stirred at RT for 16 h. The reaction mixture was diluted with water and the solid precipitated was filtered and dried. The residue obtained was purified by flash column chromatography to yield 200 mg of the desired product.1HNMR (400 MHz, DMSO-d6): δ 3.12 (s, 3H), 5.06 (q, J= 8.4 Hz,2H), 5.30 (d, J= 112 Hz,1H), 5.76 (d, J= 176 Hz,1H), 6.61-6.68 (m, 1H), 6.78 (d, J= 7.6 Hz,1H), 7.32 (t, J= 8.4 Hz,1H), 7.68 (bs, 2H), 7.84 (d, J= 8.0 Hz,1H), 8.09 (s, 1H), 8.16 (d, J= 8.0 Hz,1H), 8.27 (s, 1H), 8.46 (s, 1H), 8.70 (s,1H), 11.72 (s, 1H).; ESI-MS (m / z) 505.3 (M+H)+. Step-2: N-(4'-cyano-2'-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-3-yl)-5-formyl-2- oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3-carboxamide To a stirred solution of N-(4'- triazol-3-yl)-[1,1'-biphenyl]-3-yl)- 2-oxo-1-(2,2,2-trifluoroethyl)-5-vinyl-1,2-dihydropyridine-3-carboxamide (200 mg, 0.39 mmol) in THF / H2O (10 mL) was added NaIO4(170 mg, 0.08 mmol) followed by 1% OsO4in t-BuOH (2 mg, 0.08 mmol) at 0 °C. The reaction mixture was stirred at RT for overnight. The reaction mixture was diluted with water and extracted with chloroform. The organic layer was separated, dried over anhydrous Na2SO4and concentrated. The residue obtained was purified by flash column chromatography to yield 160 mg of the desired compound.1HNMR (400 MHz, DMSO-d6): δ 3.14 (s, 3H), 5.17(q, J= 8.4 Hz,2H), 6.82 (d, J= 7.6 Hz,1H), 7.33 (t, J= 7.6 Hz,1H), 7.66-7.69 (m, 2H), 7.85 (d, J= 8.0 Hz,1H), 8.10 (s, 1H), 8.16 (d, J= 8.0 Hz,1H), 8.47 (s, 1H), 8.76 (s, 1H), 8.96 (s,1H), 9.81 (s,1H), 11.29 (s, 1H).; ESI-MS (m / z) 507.2 (M+H)+. Step-3: (S)-N-(4'-cyano-2'-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-3-yl)-5-((3- methylpiperidin-1-yl)methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3- carboxamide To a stirred solution of (3S)-3-methylpiperidine HCl (28 mg, 0.207 mmol) in DCE (3 mL) was added triethylamine (42 mg, 0.414 mmol) and stirred for 10 min. To this reaction mixture was added N-(4'-cyano-2'-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-3-yl)-5-formyl-2-oxo- 1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3-carboxamide (70 mg, 0.138 mmol) and stirred at RT for 3 h. To this mixture was added sodium triacetoxyborohydride (110 mg, 0.519 mmol) and stirred at RT for overnight. The reaction mixture was quenched with aqueous sodium bicarbonate solution and extracted twice with ethyl acetate. The organic layer was concentrated under reduced pressure and the residue obtained was purified by silica gel flash chromatography to yield 12 mg of the desired product.1H NMR (400 MHz, DMSO-d6): δ 0.81 (d, J=4.4 Hz, 3H), 1.55-1.67 (m, 4H), 1.87-1.91 (m, 1H), 2.72-2.73 (m, 2H), 3.11 (s, 3H), 3.37-3.40 (m, 2H), 3.90 (s, 2H), 5.08 (q, J=8.8 Hz, 2H), 6.78 (d, J= 8.0 Hz, 1H), 7.31 (t, J= 8.0 Hz,1H), 7.65-7.67 (m, 2H), 7.84 (d, J= 8.0 Hz, 1H), 8.01 (s, 1H), 8.08 (s, 1H), 8.15 (d, J= 8.0 Hz, 1H), 8.31 (s, 1H), 8.45 (s, 1H), 11.85 (s, 1H); ESI-MS (m / z) 590.4 (M+H)+. Example-2 N-(4'-cyano-2'-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-3-yl)-5- ((isobutylamino)methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3-carboxamide To a stirred solution of isobutyl and N-(4'-cyano-2'-(4-methyl- 4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-3-yl)-5-formyl-2-oxo-1-(2,2,2-trifluoroethyl)-1,2- dihydropyridine-3-carboxamide (Step 2 Intermediate of Example 1) (70 mg, 0.138 mmol) in DCE (5 mL) was added acetic acid (17 mg, 0.296 mmol) and heated to reflux for 3 h. The reaction was cooled to 0 °C and added sodium triacetoxy borohydride (94 mg, 0.444 mmol) portion wise and stirred at RT for 16 h. The reaction mixture was quenched with aqueous sodium bicarbonate solution and extracted twice with ethyl acetate. The organic layer was concentrated under reduced pressure and the residue obtained was purified by flash chromatography to yield 11 mg of the desired product.1H NMR (400 MHz, DMSO-d6): δ 0.86 (d, J=6.4 Hz, 6H), 1.64-1.69 (m, 1H), 2.32 (d, J= 6.8 Hz, 2H), 3.12 (s, 3H), 3.58 (s, 2H), 5.08 (q, J=8.8 Hz, 2H), 6.78 (d, J= 8.0 Hz, 1H), 7.31 (t, J= 8.0 Hz, 1H), 7.66-7.68 (m, 2H), 7.84 (d, J= 8.4 Hz,1H), 8.02 (s, 1H), 8.09 (s, 1H), 8.15 (d, J= 8.0 Hz, 1H) 8.45 (s, 1H), 8.56 (s, 1H), 11.87 (s, 1H); ESI-MS (m / z) 564.4 (M+H)+. The details of synthesis and analytical data of the examples synthesized from the above- mentioned methods are given below in Table 3. Table 3: Structure, method, intermediates used, chemical name and analytical data of Examples 3 to 31. Ex. No. Structure & Chemical Name Intermediates Analytical data / Method 3 A2 & B11H NMR (400 MHz, DMSO- Isobutylamine d6)1H NMR (400 MHz, / Method A DMSO-d6) ^ 0.86(d, 5-((Isobutylamino)methyl)-N-(2'- J=6.4Hz,6H), 1.63-1.68 (m, (4-methyl-4H-1,2,4-triazol-3-yl)- 1H), 2.27 (d, J= 6.8Hz, 2H), [1,1'-biphenyl]-3-yl)-2-oxo-1- 3.04 (s, 3H), 3.56 (s, 2H), 5.05 (2,2,2-trifluoroethyl)-1,2- -5.11 (m,2H), 6.76 (d, J=7.2 dihydropyridine-3-carboxamide Hz,1H), 7.27 (t, J=7.6Hz, 1H), 7.55- 7.71 (m, 6H), 8.02 (s,1H), 8.39 (s,1H), 8.55(d, J= 2Hz,1H), 11.86 (s, 1H); ESI- MS(m / z)539.23 (M+H)+4 A1 & B11H NMR (400 MHz, DMSO- Isobutylamine d6);1H NMR (400 MHz, / Method A DMSO-d6) ^ 0.87 (d, J = 6.8, 6H), 1.30-1.35 (m, 1H), 2.29- N-(4'-Fluoro-2'-(4-methyl-4H- 2.38 (m, 2H), 3.09(s, 3H), 1,2,4-triazol-3-yl)-[1,1'- 3.67 (s, 2H), 5.05-5.12(m, biphenyl]-3-yl)-5- 2H), 6.76 (d, , J=7.6Hz,1H), ((isobutylamino)methyl)-2-oxo- 7.28 (t, J=8Hz, 1H), 7.45- 1-(2,2,2-trifluoroethyl)-1,2- 7.48(dd, J=2.8 & 9.2Hz, 1H), dihydropyridine-3-carboxamide 7.53-7.69(m, 4H), 8.06 (s, 1H), 8.41 (s, 1H), 8.60 (s, 1H), 11.81 (s, 1H) ; ESI-MS (m / z) 557.2 (M+H)+ Ex. No. Structure & Chemical Name Intermediates Analytical data / Method 5 A1 & B11H NMR (400 MHz, DMSO- (S)-3-methyl d6) ^ 0.83-0.87 (m, 3H), 1.24- piperidine 1.28 (m, 2H), 1.44-1.48 (m, HCl 1H), 1.56-1.67 (m, 2H), 1.86- (S)-N-(4'-Fluoro-2'-(4-methyl- / Method A 1.89 (m,1H), 2.68-2.73 (m, 4H-1,2,4-triazol-3-yl)-[1,1'- 2H), 3.09(s, 3H), 3.37-3.40 biphenyl]-3-yl)-5-((3- (m, 4H), 5.08 (q, J=8.4 Hz, methylpiperidin-1-yl)methyl)-2- 2H), 6.74 (d, J=7.2Hz, oxo-1-(2,2,2-trifluoroethyl)-1,2- 1H),7.27(t, J=7.6Hz,1H), dihydropyridine-3-carboxamide 7.46 (d, J= 9.2Hz, 1H), 7.55- 7.69(m, 4H), 8.01 (s, 1H), 8.41 (s, 1H), 8.46 (s, 1H), 11.82 (s, 1H) ; ESI-MS (m / z) 583.1 (M+H)+6 A4 & B11H NMR (400 MHz, DMSO- Isobutylamine d6) ^1H NMR (400 MHz, / Method A DMSO-d6) ^ 0.89 – 0.88 (d, J = 6.8 Hz, 6H), 1.68-1.74 (m, N-(4,4'-Difluoro-2'-(4-methyl- 1H), 2.31-2,33 (m, 2H), 3.18 4H-1,2,4-triazol-3-yl)-[1,1'- (s, 3H), 3.67-3.69 (m, 2H), biphenyl]-3-yl)-5- 5.11 (q, J=9.2, 2H), 6.83 (bs, ((isobutylamino)methyl)-2-oxo- 1H), 7.30 – 7.26 (m, 1H), 7.50 1-(2,2,2-trifluoroethyl)-1,2- – 7.47 (m, 1H), 7.58 – 7.53 dihydropyridine-3-carboxamide (m, 1H), 7.66 – 7.62 (m, 1H), 8.09 (s, 1H), 8.28 (d, J = 4.2 Hz, 1H), 8.42 (s, 1H), 8.61 (s, 1H), 12.13(s,1H);ESI- MS(m / z)575.33 (M+H)+. Ex. No. Structure & Chemical Name Intermediates Analytical data / Method 7 A3 & B11H NMR (400 MHz, DMSO- Isobutylamine d6) ^1H NMR (400 MHz, / Method A DMSO-d6) ^ 0.87 (d, J = 6.8, N-(5'-Fluoro-2'-(4-methyl-4H- 6H), 1.65-1.71 (m, 1H), 2.30 1,2,4-triazol-3-yl)-[1,1'- (d, J= 6.4 Hz, 2H), 3.05 (s, biphenyl]-3-yl)-5- 3H), 3.59 (s, 2H), 5.08 (q, ((isobutylamino)methyl)-2-oxo- J=9.2 Hz, 2H), 6.77-6.79 1-(2,2,2-trifluoroethyl)-1,2- (m,1H),7.27- 7.29 (m, 1H), dihydropyridine-3-carboxamide 7.43 (t, J=8.4Hz,1H), 7.50- 7.53 (m, 1H), 7.60-7.62 (m, 2H), 7.68 (d, J=8.4Hz, 1H), 8.03 (s, 1H), 8.39 (s, 1H), 8.57 (s, 1H) 11.85 (s, 1H); ESI- MS(m / z)557.36 (M+H)+8 A6 & B11H (400 MHz, DMSO-d6) ^ Isobutylamine 0.87(d, J=6.8 Hz, 6H), 1.67- / Method A 1.70(m, 1H), 2.31-2.33(m, 2H), 3.21(s, 3H), 3.60-3.61 (s, N-(4'-Cyano-4-fluoro-2'-(4- 2H), 5.10 (q, J=9.2 Hz, 2H), methyl-4H-1,2,4-triazol-3-yl)- 6.88-6.90 (m, 1H), 7.31-7.35 [1,1'-biphenyl]-3-yl)-5- (m, , 1H), 7.81 (d, J=8 Hz, ((isobutylamino)methyl)-2-oxo- 1H), 8.06-8.17 (m, 3H), 8.32- 1-(2,2,2-trifluoroethyl)-1,2- 8.34 (m, 1H) 8.46 (s, 1H), dihydropyridine-3-carboxamide 8.59 (s, 1H), 12.20 (s, 1H); ESI-MS (m / z) 581.58 (M+H) + 9 A13 & B11H NMR (400 MHz, DMSO- Isobutylamine d6): δ 0.87 (d, J = 6.8 Hz, 6H), / Method A 1.69-1.70 (m, 1H), 1.91 (s, 3H), 2.33-2.34 (m,2H), 3.64 Ex. No. Structure & Chemical Name Intermediates Analytical data / Method N-(4'-Fluoro-2'-(5-methyl-1H- (bs, 2H), 5.12 (q, J = 8.8 Hz, 1,2,3-triazol-1-yl)-[1,1'- 2H), 6.51 (d, J = 7.6 Hz, 1H), biphenyl]-3-yl)-5- 7.22-7.26 (m, 1H), 7.50-7.51 ((isobutylamino)methyl)-2-oxo- (m, 2H), 7.59-7.65 (m,3H), 1-(2,2,2-trifluoroethyl)-1,2- 7.71-7.76 (m,1H), 8.04 (s, dihydropyridine-3-carboxamide 1H), 8.58 (s, 1H), 11.80 (brs, Exchangeable with D2O, 1H).; ESI-MS (m / z) 557.44 (M+H)+10 A14 & B11HNMR (400 MHz, DMSO- Isobutylamine d6): δ 0.87 (d, J= 6.4 Hz,6H), / Method A 1.61-1.68 (m, 4H), 2.31 (d, J= 6.4 Hz,2H), 3.60 (s, 2H), 5.07 N-(4'-Fluoro-2'-(5-methyl-1H- (q, J= 9.2 Hz,2H), 6.75 (d, 1,2,3-triazol-4-yl)-[1,1'- J=7.6 Hz, 1H), 7.23-7.41 (m, biphenyl]-3-yl)-5- 3H), 7.53-7.57 (m, 3H), 8.02 ((isobutylamino)methyl)-2-oxo- (s,1H), 8.56 (s, 1H), 11.82 (s, 1-(2, 2,2-trifluoroethyl)-1,2- 1H), 14.59 (m,1H); ESI-MS dihydropyridine-3-carboxamide (m / z) 557.41(M+H)+11 A7 & B11H NMR (400 MHz, DMSO- Isobutylamine d6) ^ 0.89 (d, J = 6.8 Hz, / Method A 6H),1.72-1.73 (m, 1H), 2.33 – 2.41 (m, 2H), 3.33 (s, 3H), N-(4-(4-Fluoro-2-(4-methyl-4H- 3.70 (s, 2H), 5.09 (q, J= 8.8 1,2,4-triazol-3-yl)phenyl)pyridin- Hz, 2H), 6.86 (d, J = 4.0 Hz, 2-yl)-5-((isobutylamino)methyl)- 1H),7.58-7.64 (m, 2H), 7.71- 2-oxo-1-(2,2,2-trifluoroethyl)- 7.74 (m, 1H), 8.01 (s, 1H), 1,2-dihydropyridine-3- 8.05-8.06 (m, 1H), 8.26 (d, J carboxamide = 5.2 Hz, 1H), 8.48 (s, 1H), 8.56-8.62 (m, 1H), 12.22 (s, Ex. No. Structure & Chemical Name Intermediates Analytical data / Method 1H),; ESI-MS (m / z) 558.4 (M+H)+12 A5 & B11H NMR (400 MHz, DMSO- Isobutylamine d6) ^ 0.88 (d, J = 6.8 Hz, 6H), / Method A 1.69-1.71 (m, 1H), 2.33 (s, 2H), 3.22 (s, 3H), 3.63 (brs, N-(4-Chloro-4'-fluoro-2'-(4- 2H), 5.09 (q, J= 8.8 Hz, 2H), methyl-4H-1,2,4-triazol-3-yl)- 6.81 (d, J = 8.4 Hz, 1H), 7.47 [1,1'-biphenyl]-3-yl)-5- – 7.52 (m, 2H), 7.55– 7.60 (m, ((isobutylamino)methyl)-2-oxo- 1H), 7.64 – 7.67 (m, 1H), 8.07 1-(2,2,2-trifluoroethyl)-1,2- (s, 1H), 8.38 (s, 1H), 8.44 (s, dihydropyridine-3-carboxamide 1H), 8.61 (s, 1H), 12.25 (s, 1H) ;ESI-MS (m / z) 591.82 (M+H)+. 13 A1 & B21H NMR (400 MHz, DMSO- Isobutylamine d6) ^ 0.45 – 0.46 (m,2H), 0.53 / Method A – 0.49 (m, 2H), 0.89 – 0.88 (d, 1-(Cyclopropylmethyl)-N-(4'- J = 6.8 Hz, 6H), 1.35 – 1.34 fluoro-2'-(4-methyl-4H-1,2,4- (m, 1H), 1.71-1.73 (m, 1H), triazol-3-yl)-[1,1'-biphenyl]-3- 2.36 (s, 2H), 3.10 (s, 3H), 3.63 yl)-5-((isobutylamino)methyl)-2- (brs, 2H), 3.93 – 3.95 (d, J = oxo-1,2-dihydropyridine-3- 7.2 Hz, 2H), 6.73 – 6.75 (d, J carboxamide = 7.2 Hz, 1H), 7.25 – 7.29 (m, 1H), 7.53 – 7.58 (m, 1H), 7.62 – 7.69 (m, 4H), 8.11 (s, 1H), 8.42 (s, 1H), 8.52 (s, 1H), 12.27 (s, 1H);ESI-MS (m / z) 529.36 (M+H)+. Ex. No. Structure & Chemical Name Intermediates Analytical data / Method 14 A8 & B11H (400 MHz, DMSO-d6) ^ Isobutylamine 0.87(d, J=6.8 Hz, 6H), 1.66- / Method A 1.71(m, 1H), 2.30(d, J=4.8 Hz, 2H), 3.19(s, 3H), 3.59(s, N-(4',5-Difluoro-2'-(4-methyl- 2H), 5.08 (q, J= 9.2 Hz,2H), 4H-1,2,4-triazol-3-yl)-[1,1'- 6.58(d, J=9.6 Hz, 1H), 7.23(s, biphenyl]-3-yl)-5- 1H), 7.50(dd, J1=2.84 Hz, ((isobutylamino)methyl)-2-oxo- J2=2.64 Hz, 1H), 7.54- 1-(2,2,2-trifluoroethyl)-1,2- 7.59(m, 2H), 7.69-7.73(m, dihydropyridine-3-carboxamide 2H), 8.04(s, 1H), 8.57(d, J=2.4 Hz, 1H), 11.95(bs, 1H); ESI-MS (m / z) = 575.36 (M+H)+151H NMR (400 MHz, DMSO- A9 / B1 d6) 0.85 (d, J = 6.4 Hz, 6H), Isobutylamine 1.68 (m,1H), 2.33 (s, 2H), Method A 3.29 ( s,3H), 3.61 (s,2H), 5.08 N-(2,4'-Difluoro-2'-(4-methyl- (q, J=8.8 Hz,2H), 6.74-6.77 4H-1,2,4-triazol-3-yl)-[1,1'-bi (m,1H),7.09-7.13 (t, J = 8.0 phenyl]-3-yl)-5-((isobutylamino) Hz, 1H), 7.48-7.60 (m, 2H), methyl)-2-oxo-1-(2,2,2-trifluoro 7.65-7.69 (t, J = 8.0 Hz, 1H), ethyl)-1,2-dihydropyridine-3- 7.69 (s, 1H), 8.39-8.45 carboxamide (m,2H), 8.61(s,1H), 12.13 (s,1H); ESI-MS (m / z) 575.36 (M+H)+16 A1 / B11H NMR (400 MHz, DMSO- Cyclopropyl d6) ^ 0.11 – 0.12 (m, 2H), 0.39 methanamine – 0.44 (m, 2H), 0.85 – 0.90 Method A 5-(((Cyclopropylmethyl)amino) (m, 1H), 2.40 – 2.42 (m, 2H), methyl)-N-(4'-fluoro-2'-(4-meth 3.09 (s, 3H), 3.65 (s, 2H), 5.08 yl-4H-1,2,4-triazol-3-yl)-[1,1'-bi (q, J = 8.8 Hz, 2H), 6.75 (d, J Ex. No. Structure & Chemical Name Intermediates Analytical data / Method phenyl]-3-yl)-2-oxo-1-(2,2,2- = 7.6 Hz, 1H), 7.26 (t, J = 8 trifluoroethyl)-1,2-dihydropyridi Hz, 1H), 7.45 – 7.48 (m, 1H), ne-3-carboxamide 7.53 – 7.69 (m, 4H), 8.05 (s, 1H), 8.42 (s, 1H), 8.57 (s, 1H), 11.83 (s, 1H), ESI-MS (m / z) 555.2 (M+H)+17 A1 / B11H NMR (400 MHz, DMSO- Method A d6) ^ 1.75 (s, 3H), 1.66 – 1.82 1- (m, 4H), 1.95 – 2.06 (m, 2H), methylcyclo 3.09 (s, 3H), 3.65 (s, 2H), 5.08 N-(4'-Fluoro-2'-(4-methyl-4H- butan-1- (q, J = 8.8 Hz, 2H), 6.76 (d, J 1,2,4-triazol-3-yl)-[1,1'- amine = 7.6 Hz, 1H), 7.28 (t, J = 8 biphenyl]-3-yl)-5-(((1- HCl Hz, 1H), 7.45 – 7.48 (m, 1H), methylcyclobutyl)amino)methyl)- 7.53 – 7.69 (m, 4H), 8.11 (s, 2-oxo-1-(2,2,2-trifluoroethyl)- 1H), 8.42 (s, 1H), 8.60 (s, 1H), 1,2-dihydropyridine-3- 11.80 (s, 1H); ESI-MS (m / z) carboxamide 569.6 (M+H)+18 A7 / B31H NMR (400 MHz, DMSO- Isobutylamine d6) ^ 0.89(d, J = 6.4 Hz, 6H), Method A 1.68-1.73 (m,1H), 2.35-2.39 (m, 2H), 3.34 (s, 3H), 3.62 (s, N-(4-(4-Fluoro-2-(4-methyl-4H- 3H), 3.65 (s, 2H), 6.81-6.84 1,2,4-triazol-3-yl)phenyl)pyridin- (dd, J = 5.2 Hz, J = 1.6 Hz 2-yl)-5-((isobutylamino)methyl)- 1H)), 7.64-7.57 (m, 2H), 7.70- 1-methyl-2-oxo-1,2- 7.74 (m, 1H), 8.04 (s, 1H), dihydropyridine-3-carboxamide 8.14 (s, 1H), 8.25(d, J = 5.2 Hz,1H), 8.49 (s,1H), 8.52(d, J = 2.4 Hz,1H), 12.59 (s, 1H),; ESI-MS (m / z) 490.1 (M+H)+. Ex. No. Structure & Chemical Name Intermediates Analytical data / Method 19 A10 / B11H NMR (400 MHz, DMSO- Isobutylamine d6) ^ 0.87 (d, J = 6.4 Hz, 6H), Method A 1.64 – 1.71 (m, 1H), 2.29 – 2.33 (m, 2H), 3.07 (s, 3H), N-(4'-Chloro-2'-(4-methyl-4H- 3.58 (s, 2H), 5.08 (q, J = 8.8 1,2,4-triazol-3-yl)-[1,1'-biphe Hz, 2H), 6.75 (d, J = 7.6 Hz, nyl]-3-yl)-5-((isobutylamino) 1H), 7.28 (t, J = 8 Hz, 1H), methyl)-2-oxo-1-(2,2,2-trifluoro 7.60 – 7.67 (m, 4H), 7.75 – ethyl)-1,2-dihydropyridine-3- 7.78 (m, 1H), 8.02 (s, 1H), carboxamide 8.41 (s, 1H), 8.56 (s, 1H), 11.85 (s, 1H); ESI-MS (m / z) 574.3 (M+H)+20 A1 / B41H NMR (400 MHz, DMSO- Isobutylamine d6) ^ 0.90 (d, J = 6.8 Hz, 6H), Method A 0.96-0.99(m, 2H), 1.09- 1.14(m, 2H), 1.75-1.91 (m, 1-Cyclopropyl-N-(4'-fluoro-2'-(4- 1H), 2.44-2.48(m, 2H), methyl-4H-1,2,4-triazol-3-yl)- 3.10(s, 3H), 3.48-3.53 (m, [1,1'-biphenyl]-3-yl)-5- 1H), 3.73 (s, 2H), 6.75 (d, ((isobutylamino)methyl)-2-oxo- J=7.6 Hz, 1H), 7.28(t, J=8 Hz, 1,2-dihydropyridine-3- 1H), 7.46-7.48(m, 1H), 7.53- carboxamide 7.59( m, 2H), 7.63-7.70(m, 2H), 8.00(s,1H), 8.42(s, 1H), 8.52(d, J= 2.4 Hz, 1H), 12.21 (s,1H); ESI-MS (m / z) 515.6 (M+H)+21 A11 / B11H NMR (400 MHz, DMSO- Isobutylamine d6): ^ 0.87 (d, J= 6.4 Hz, 6H), Method A 1.65 – 1.69 (m, 1H), 2.31-2.35 (m, 2H), 3.11 (s, 3H), 3.60 (s, 2H), 5.07 (q, J = 8.8 Hz, 2H), Ex. No. Structure & Chemical Name Intermediates Analytical data / Method N-(4',5'-Difluoro-2'-(4-methyl- 6.76 (d, J= 7.6 Hz, 1H), 7.28 4H-1,2,4-triazol-3-yl)-[1,1'- (t, J= 7.6 Hz, 1H), 7.57 (s, biphenyl]-3-yl)-5- 1H), 7.68-7.81 (m, 3H), 8.03 ((isobutylamino)methyl)-2-oxo- (s, 1H), 8.42 (s, 1H), 8.57 (s, 1-(2,2,2-trifluoroethyl)-1,2- 1H), 11.85 (s, 1H); ESI-MS dihydropyridine-3-carboxamide (m / z) 575.4 (M+ H)+22 A1 / B11H NMR (400 MHz, DMSO- Neopentyl d6) ^ 0.86 (s, 9H), 2.21 (s, amine 2H), 3.09 (s, 3H), 3.60 (s, 2H), Method A 5.08 (q, J = 8.8 Hz, 2H), 6.74 N-(4'-Fluoro-2'-(4-methyl-4H- (d, J = 8.4 Hz, 1H), 7.27 (t, J 1,2,4-triazol-3-yl)-[1,1'- = 8 Hz, 1H), 7.45 – 7.48 (m, biphenyl]-3-yl)-5- 1H), 7.53 – 7.69 (m, 4H), 8.01 ((neopentylamino)methyl)-2-oxo- (s, 1H), 8.41 (s, 1H), 8.56 (s, 1-(2,2,2-trifluoroethyl)-1,2- 1H), 11.85 (s, 1H), ESI-MS dihydropyridine-3-carboxamide (m / z) 571.5 (M+H)+. 23 A1 / B11H NMR (400 MHz, DMSO- 3- d6) ^ 0.85 (d, J = 6.4 Hz, 6H), methylbutan- 1.31-1.35(m, 2H), 1.58- 1-amine 1.63(m, 1H),2.53-2.55(m, N-(4'-Fluoro-2'-(4-methyl-4H- Method A 2H), 3.09(s, 3H), 3.63(s, 2H), 1,2,4-triazol-3-yl)-[1,1'-biphen 5.09 (q, J = 8.8 Hz, 2H), yl]-3-yl)-5-((isopentylamino) 6.76(d, J=8.0 Hz,1H), 7.28(t, methyl)-2-oxo-1-(2,2,2-trifluoro J=8.0 Hz, 1H), 7.45-7.48(m, ethyl)-1,2-dihydropyridine-3- 1H), 7.53-7.58( m, 2H), 7.61- carboxamide 7.70(m, 2H), 8.04(s,1H), 8.41(s, 1H), 8.56(d, J= 2.4 Hz, 1H), 11.82 (s,1H); ESI-MS (m / z) 571.4 (M+H)+ Ex. No. Structure & Chemical Name Intermediates Analytical data / Method 24 A1 / B11H NMR (400 MHz, DMSO- 4,4-difluoro- d6) ^ 0.93 (d, J = 6.8 Hz, 3H), 3-methyl pip 2.00-2.26 (m, 4H), 2.26-2.29 eridine HCl (m, 1H), 2.75-2.76 (m, 2H), 5-((4,4-Difluoro-3-methylpiper Method A 3.09 (s, 3H), 3.44 (s, 2H), 5.08 idin-1-yl)methyl)-N-(4'-fluoro-2'- (q, J = 8.8 Hz, 2H), 6.75 (d, (4-methyl-4H-1,2,4-triazol-3-yl)- J=7.6 Hz, 1H), 7.26 (t, J=8.0 [1,1'-biphenyl]-3-yl)-2-oxo-1- Hz, 1H), 7.45-7.48(m, 1H), (2,2,2-trifluoroethyl)-1,2- 7.55-7.63 (m, 3H), 7.67-7.69( dihydropyridine-3-carboxamide m, 1H), 8.05 (s, 1H), 8.41(s, 1H), 8.49( d, J= 2.4 Hz, 1H), 11.80 (s, 1H); ESI-MS (m / z) 618.8 (M+H)+25 A11 / B11H NMR (400 MHz, DMSO- 1- d6): ^ 1.71-1.91 (m, 5H), 2.03- methylcyclo 2.06 (m, 2H), 2.83-2.85 (m, butan-1- 2H), 3.17 (s, 3H), 3.93 (s, 2H), N-(4',5'-Difluoro-2'-(4-methyl- amine 5.07-5.13 (m, 2H), 6.82 (d, J= 4H-1,2,4-triazol-3-yl)-[1,1'-bip HCl 5.6 Hz, 1H), 7.31 (t, J= 8 Hz, henyl]-3-yl)-5-(((1-methylcyclo Method A 1H),7.54 (s, 1H), 7.70- butyl)amino)methyl)-2-oxo-1- 7.80(m, 3H), 8.14 (s, 1H), (2,2,2-trifluoroethyl)-1,2-dihy 8.41 (s, 1H), 8.68 (s, 1H), dropyridine-3-carboxamide 11.72 (s, 1H); ESI-MS (m / z)586.8 (M)+26 A16 / B11H NMR (400 MHz, DMSO- Isobutylamine d6) ^ 0.82 - 0.88 (m, 4H), 1.70- Method A 1.71(m, 1H), 1.97-2.0 (m, 1H), 2.31(d, J=6.0Hz, 2H), N-(6-Cyclopropyl-4-(4-fluoro-2- 3.28 (s, 3H), 3.64 (s, 2H), 5.09 (4-methyl-4H-1,2,4-triazol-3- (q, J = 8.8 Hz, 2H), 6.75(s, yl)phenyl)pyridin-2-yl)-5- 1H), 7.55-7.62 (m, 2H), 7.70- Ex. No. Structure & Chemical Name Intermediates Analytical data / Method ((isobutylamino)methyl)-2-oxo- 7.74(m, 2H), 8.06 (s, 1H), 1-(2,2,2-trifluoroethyl)-1,2- 8.48 (s, 1H), 8.58(s, 1H), dihydropyridine-3-carboxamide 12.04(s, 1H) ESI-MS (m / z) 598.1 (M+H)+27 A16 / B11H NMR (400 MHz, DMSO- 1- d6) ^ 0.79-0.82(m, 2H), 0.91- methylcyclo 0.94 (m, 2H),1.61-1.65(m, butan-1- 2H), 1.77-1.85(m, 3H), 1.95- amine 2.01(m, 3H), 2.39-2.46(m, N-(6-Cyclopropyl-4-(4-fluoro-2- HCl 2H), 3.39(s, 3H), 3.58(s, 2H), (4-methyl-4H-1,2,4-triazol-3- Method A 5.09 (q, J = 8.8 Hz, 2H), yl)phenyl)pyridin-2-yl)-5-(((1- 6.74(d, J=1.2Hz, 1H), 7.55- methylcyclobutyl)amino)methyl)- 7.62(m, 2H), 7.70-7.74(m, 2-oxo-1-(2,2,2-trifluoroethyl)- 2H),8.03(s, 1H),8.49(s, 1H), 1,2-dihydropyridine-3- 8.55(d, J=2.4Hz, 1H), carboxamide 12.06(s,1H): ESI-MS (m / z) 610.8 (M+H)+28 A15 / B11H NMR (400 MHz, DMSO- Isobutylamine d6) ^ 0.88 (d, J=6.8Hz, 6H), Method A 1.71-1.74 (m,1H), 2.35 (m,2H), 2.36 (m,3H), 3.38 N-(6-(4-Fluoro-2-(4-methyl-4H- (s,3H), 3.66 (s,2H), 5.14 (q, J 1,2,4-triazol-3-yl)phenyl)-2- = 9.2 Hz , 2H), 7.53-7.62 (m, methylimidazo[1,2-a]pyridin-8- 2H), 7.69-7.73 (m, 2H), 7.89 yl)-5-((isobutylamino)methyl)-2- (d, J =1.2 Hz, 1H), 8.06 oxo-1-(2,2,2-trifluoroethyl)-1,2- (s,1H), 8.10 (s,1H), 8.44 dihydropyridine-3-carboxamide (s,1H), 8.59 (s,1H), 12.42 (s,1H); ESI-MS (m / z) 611.1 (M+H)+ Ex. No. Structure & Chemical Name Intermediates Analytical data / Method 29 A15 / B31H NMR (400 MHz, DMSO- Isobutylamine d6) ^ 0.89 (d, J=6.8 Hz, 6H), Method A 1.71-1.74 (m,1H), 2.33-2.36 (m, 5H), 3.39 (s, 3H), 3.62 (s, 2H), 3.65 (s, 3H), 7.53-7.60 N-(6-(4-Fluoro-2-(4-methyl-4H- (m,2H), 7.67-7.72 (m,2H), 1,2,4-triazol-3-yl)phenyl)-2- 7.90 (d, J = 1.6 Hz, 1H), 8.06 methylimidazo[1,2-a]pyridin-8- (d, J = 1.6 Hz, 1H), 8.11 (s, yl)-5-((isobutylamino)methyl)-1- 1H), 8.44 (s, 1H), 8.49 (d, J = methyl-2-oxo-1,2- 2.4 Hz, 1H), 12.79 (s,1H) dihydropyridine-3-carboxamide ESI-MS (m / z) 542.8 (M+H)+30 A18 / B11H NMR (400 MHz, DMSO- Isobutylamine d6): ^ 0.90 (d, J = 6.8Hz, 6H), Method A 1.72 -1.75 (m, 1H), 2.30-2.33 (m, 2H), 3.28(s, 2H), 3.70 (s, N-(6-(4-Fluoro-2-(4-methyl-4H- 3H),5.15 (q, J = 9.2 Hz, 2H), 1,2,4-triazol-3- 7.49 (s, 1H), 7.56-7.66 (m, yl)phenyl)quinolin-8-yl)-5- 3H), 7.77-7.81 (m, 1H), 8.07 ((isobutylamino)methyl)-2-oxo- (s, 1H), 8.32 ( s, 1H), 8.39 (s, 1-(2,2,2-trifluoroethyl)-1,2- 1H), 8.65-8.68 (m, 2H), 8.96- dihydropyridine-3-carboxamide 8.97 (m, 1H), 13.18 (s, 1H) ; ESI-MS (m / z) 608.3 (M+H)+31 A17 / B11H NMR (400 MHz, DMSO- Isobutylamine d6): ^ 0.82 (d, J = 6.8 Hz, 6H), Method A 1.70 – 1.73 (m, 1H), 2.35 (d, J = 5.6 Hz, 2H), 3.29(s, 3H), 5-((Isobutylamino)methyl)-N-(3- 3.64 (s, 2H), 3.99 (s, 3H), (1-methyl-4-(4-methyl-4H-1,2,4- 5.07(q, J= 8.4 Hz, 2H), 7.04 triazol-3-yl)-1H-pyrazol-3- (d, J = 7.6 Hz, 1H), 7.31(t, J = yl)phenyl)-2-oxo-1-(2,2,2- 7.6 Hz, 1H), 7.62 (d, J = 7.6 Hz, 1H), 7.93 (s, 1H), 8.05(s, Ex. No. Structure & Chemical Name Intermediates Analytical data / Method trifluoroethyl)-1,2- 1H), 8.16 (s, 1H), 8.56 (s, 1H), dihydropyridine-3-carboxamide 8.59 (s, 1H), 11.86 (bs, 1H); ESI-MS (m / z) 543.5 (M+H)+Method-B Example 32 (S)-N-(6-(4-Fluoro-2-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-1-methyl-1H- benzo[d]imidazol-4-yl)-5-((3-methylpiperidin-1-yl) methyl)-2-oxo-1-(2,2,2-trifluoroethyl)- 1,2-dihydropyridine-3-carboxamide Step-1: N-(6-Bromo-1- -2-oxo-1-(2,2,2-trifluoroethyl)-5- vinyl-1,2-dihydropyridine-3-carboxamide To a stirred 2-oxo-1-(2,2,2- - 3-carboxylic acid (Intermediate B1) (360 mg, 1.454 mmol) in DMF (4.0 mL) was added HATU (830.2 mg, 2.185 mmol) and was stirred at RT for 30 min then added DIPEA (747 µl, 4.369 mmol) and 6-bromo- 1-methyl-1H-benzo[d]imidazol-4-amine (Intermediate A19) (296 mg, 1.311 mmol) and stirred at RT for 18 h. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was separated, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue thus obtained was purified by silica gel column chromatography to obtain 480 mg of the desired product.1H NMR (400 MHz, DMSO-d6) ^ 3.85(s, 3H), 5.11 (q, J = 8.8 Hz, 2H), 5.32 (d, J=11.2 Hz, 1H), 5.78 (d, J=17.6 Hz, 1H), 6.63-6.70 (m, 1H), 7.64 (d, J=1.6 Hz, 1H), 8.24 (s, 1H), 8.30 (s, 1H), 8.50 (d, J=1.6 Hz, 1H), 8.77 (d, J=2.8 Hz, 1H), 12.6 (bs, 1H). ESI-MS (m / z) 455.2 (M+H)+. Step-2: N-(6-Bromo-1-methyl-1H-benzo[d]imidazol-4-yl)-5-formyl-2-oxo-1-(2,2,2- trifluoroethyl)-1,2-dihydropyridine-3-carboxamide To a stirred solution of N-(6-bromo-1-methyl-1H-benzo[d]imidazol-4-yl)-2-oxo-1-(2,2,2- trifluoroethyl)-5-vinyl-1,2-dihydropyridine-3-carboxamide (180 mg, 0.395 mmol) was added AcOH (30 mL) at RT and reaction mixture was warmed to 50 °C for 30 min. To the reaction mixture was added 2.5% OsO4 in t-BuOH (20 μl, 0.00198 mmol) followed by the addition of NaIO4(177.6 mg, 0.830 mmol) dissolved in water (5 mL). The reaction mixture was stirred at RT for 4 h. The reaction mixture was diluted with water and extracted twice with 15% MeOH / MDC. The organic layer was separated, dried over anhydrous Na2SO4 and concentrated to yield 220 mg of the desired product.1H NMR (400 MHz, DMSO-d6) ^ 3.86 (s, 3H), 5.24 (q, J = 8.8 Hz, 2H), 7.66 (d, J = 1.6 Hz, 1H), 8.26 (s, 1H), 8.48 (d, J = 2.0 Hz, 1H), 8.87 (d, J = 2.4 Hz, 1H), 9.00 (d, J=2.4 Hz, 1H), 9.84 (s, 1H), 12.29 (bs, 1H); ESI-MS (m / z) 457.1 (M+H)+. Step-3: (S)-N-(6-bromo-1-methyl-1H-benzo[d]imidazol-4-yl)-5-((3-methylpiper idin-1-yl) methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3-carbox amide To a stirred solution of N-(6- imidazol-4-yl)-5-formyl-2-oxo-1- (2,2,2-trifluoroethyl)-1,2-dihydropyridine-3-carboxamide (250 mg, 0.548 mmol) and S- Methyl piperidine HCl (213mg, 1.645 mmol) in 1,2-DCE (6 mL) was added DIPEA (283 μl, 1.645 mmol) and stirred for 3 h at 90 °C. To this reaction mixture was added sodium triacetoxy borohydride (348.5 mg, 1.645 mmol) and stirred at RT for overnight. The reaction mixture was quenched with sat. sodium bicarbonate solution and extracted with DCM. The organic layer was separated, dried over anhydrous Na2SO4 and concentrated, the residue thus obtained was purified by silica gel column chromatography to obtain 70 mg of the desired product. ESI-MS (m / z) 542 (M+2H)+. Step-4: (S)-N-(1-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-ben zo[d]imidazol-4-yl)-5-((3-methylpiperidin-1-yl)methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2- dihydropyridine-3-carboxamide To a degassed solution of (S)-N-(6-bromo-1-methyl-1H-benzo[d]imidazol-4-yl)-5-((3- methylpiperidin-1-yl)methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3- carboxamide (70 mg, 0.1296 mmol) and Bis(pinacolato) diboron (156.2 mg, 0.259 mmol) in 1,4 dioxane (12 mL) were added KOAc (38.17 mg, 0.389 mmol) and Pd(dppf)Cl2.DCM (5.3 mg, 0.0065 mmol). The reaction mixture again degassed with N2for 10 min and stirred at 90 ° C for 4 h. The reaction mixture was diluted with ethyl acetate and filtered. The filtrate obtained was dried over anhydrous Na2SO4and concentrated under reduced pressure to obtain 150 mg of the desired product. The crude obtained was directly proceeded for next step without further purification. ESI-MS (m / z) 588.4 (M+H)+. Step-5: (S)-N-(6-(4-Fluoro-2-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-1-methyl-1H- benzo[d]imidazol-4-yl)-5-((3-methylpiperidin-1-yl) methyl)-2-oxo-1-(2,2,2-trifluoroethyl)- 1,2-dihydropyridine-3-carboxamide To a degassed solution of (S)-N-(1-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- 1H-benzo[d]imidazol-4-yl)-5-((3-methylpiperidin-1-yl)methyl)-2-oxo-1-(2,2,2- trifluoroethyl)-1,2-dihydropyridine-3-carboxamide [148.9 mg, 0.254 mmol) and 3-(2-bromo- 5-fluorophenyl)-4-methyl-4H-1,2,4-triazole (65 mg, 0.254 mmol) in 1,4 dioxane (10 mL) and water (2 mL) were added K2CO3(105 mg, 0.761 mmol) and Pd(PPh3)4(29.3 mg, 0.0253 mmol). The reaction mixture was further degassed for 5 min using nitrogen and heated to 90 °C for 2 h. The reaction mixture was diluted with ethyl acetate and washed with water. The organic layer was separated, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue thus obtained was purified by silica gel column chromatography to obtain 8 mg of the desired product.1H (400 MHz, DMSO-d6) ^ 0.82 (d, J=5.6 Hz, 3H), 1.46-1.60(m, 4H), 1.80-1.88(m, 1H), 2.70-2.74(m, 2H), 3.12 (s, 3H), 3.30 (s, 2H), 3.37-3.40 (m, 2H), 3.83 (s, 3H), 5.11 (q, J = 8.8 Hz, 2H), 6.97(s, 1H), 7.47-7.50(m, 1H), 7.55-7.60(m, 1H), 7.69- 7.73(m, 1H), 8.01(s, 1H), 8.14(s, 1H), 8.21(s, 1H), 8.36(s, 1H), 8.49(s, 1H), 12.54 (bs, 1H); ESI-MS (m / z) 637.4 (M+H)+. BIOLOGICAL ACTIVITY Cbl-b activity inhibition assay: Cbl-b activity inhibition by the compounds of the present invention were tested by measuring the interaction between Cbl-b and Ubiquitinylated UbcH5B in a HTRF based assay format. A truncated variant of Cbl-b (with GST tag at N-terminal) (Accession number NP_733762.2) containing residues 36-427 and SRC kinase full length protein (with His tag at N-terminal) (Accession number NP_005408.1) were generated in-house by molecular biology group. UBE1 (R&D Systems), UbcH5B (Enzo) and Ubiquitin Eu-cryptate (CisBio) were incubated with 1 mM ATP for 1 h at 25 °C to generate Ubiquitinylated UbcH5B. Assay performed in 384 well plate at RT in a 10µl volume, in assay buffer containing 50 mM HEPES pH 7.5, 5 mM MgCl2, 0.01% BSA and 1 mM DTT. The compound of the present invention was preincubated (0.5% DMSO final) with 1 nM cbl-b for 1.5 h, followed by addition of 10 nM SRC kinase + 1mM ATP for another 1.5 h. Ubiquitinylated UbcH5B, 300mM EDTA and 1:200 Anti-GST mAb were added. The plate incubated at RT for 1 h and then kept in 4 °C for 16 h. The plate was read for TR-FRET signal at 665 / 620nm using Spark (Tecan). The resulting data was analysed and IC50 values were determined using nonlinear regression analysis, variable slope fitting (Graph Pad Prism version 8.4.3). The results obtained are given in Table 4. Percentage inhibition at concentrations of 1.0 µM and 10.0 µM are given in the Table 4 along with IC50(nM) details for the compounds of the present invention. “A” refers to an IC50 value of less than 50 nM, “B” refers to IC50 value in range of 50.01 to 100.0 nM, “C” refers to IC50value in range of 100.01 to 500.0 nM and “D” refers to IC50 values more than 500.1 nM. Table 4: Sr. No. Compound No. Cbl-b activity inhibition at IC50 (nM) 1 µM 10 µM 1.Example 1 90.65 91.32 A 2.Example 2 92.40 91.38 A 3.Example 3 82.32 91.40 B 4.Example 4 86.26 95.11 A 5.Example 5 91.73 94.10 A 6.Example 6 92.52 93.15 A 7.Example 7 76.76 91.20 C 8.Example 8 92.86 87.17 A Sr. No. Compound No. Cbl-b activity inhibition at IC50 (nM) 1 µM 10 µM 9.Example 9 93.67 95.81 A 10.Example 10 92.56 90.73 A 11.Example 11 88.69 96.10 A 12.Example 12 92.89 92.87 A 13.Example 13 90.88 92.16 A 14.Example 14 87.79 88.78 A 15.Example 15 92.10 93.30 A 16.Example 16 88.41 93.68 A 17.Example 17 94.05 92.03 A 18.Example 18 85.41 91.53 A 19.Example 19 89.94 71.20 A 20.Example 20 89.53 100.00 A 21.Example 21 88.93 100.00 A 22.Example 22 81.01 90.26 A 23.Example 23 95.32 97.84 A 24.Example 24 75.80 71.14 C 25.Example 25 92.16 92.88 A 26.Example 26 99.77 96.70 A 27.Example 27 87.75 86.94 A 28.Example 28 79.29 80.35 A 29.Example 29 81.07 86.33 A 30.Example 30 89.95 93.06 A 31.Example 31 25.10 65.90 D 32.Example 32 66.06 67.08 B Although the invention herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the spirit and scope of the present invention as described above. All publications and patent applications cited in this application are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated herein by reference.
Claims
WHAT IS CLAIMED IS:
1. A compound of formula (IA):or stereoisomer wherein, ring ringto 6-membered heteroaryl; X1and X2are independently represents C, N or S; ‘----’ between X1and X2represents optional bond; at each occurrence, R1is selected from halogen, C1-8alkyl, C1-8alkoxy, C1- 8alkoxy-C1-8alkyl, cyano, hydroxyl, haloC1-8alkyl and hydroxylC1-8alkyl; at each occurrence, R2is independently selected from halogen, haloC1-8alkyl, cyano, -COOH, -COO-C1-8alkyl, C1-8alkyl, C1-8alkoxy, C1-8alkoxy-C1-8alkyl, 4-6 membered heterocyclyl and C3-12cycloalkyl; wherein the said 4-6 membered heterocyclyl and C3-8cycloalkyl are substituted with one or more substituents selected from halogen, cyano, hydroxyl, C1-8alkyl, haloC1-8alkyl, hydroxylC1-8alkyl, C1-8alkoxy and C1-8alkoxy-C1-8alkyl; at each occurrence, R3is independently selected from cyano, halogen, C1-8alkyl, haloC1-8alkyl, hydroxyl, hydroxylC1-8alkyl, C1-8alkoxy, C1-8alkoxy-C1-8alkyl, -COOH, -COO-C1-8alkyl, -NRxRy, C6-10aryl, 4-6 membered heterocyclyl and C3-12cycloalkyl; wherein the said C6-10aryl, 4-6 membered heterocyclyl and C3-8cycloalkyl are unsubstituted or substituted with one or more substituents selected from halogen, cyano, hydroxyl, C1-8alkyl, cyanoC1-8alkyl, haloC1-8alkyl, C1-8alkoxy, C1-8alkoxy-C1-8alkyl and hydroxylC1-8alkyl; alternatively, any two R3groups attached to the adjacent C or N atom combine together to form 5- to 6-membered fused heteroaryl ring which is unsubstituted or substituted by one or more R3a;R3ais independently selected from halogen, cyano, hydroxyl, C1-8alkyl, haloC- 1-8alkyl, hydroxylC1-8alkyl, C1-8alkoxy and C1-8alkoxy-C1-8alkyl; Rxand Ryare independently selected from hydrogen, C1-8alkyl, haloC1-8alkyl, hydroxylC1-8alkyl, cyanoC1-8alkyl, -COO-C1-8alkyl, S(O)2C1-8alkyl, C3-12cycloalkyl, 4- 6 membered heterocyclyl and C3-8cycloalkylC1-8alkyl; wherein C3-12cycloalkyl, 4-6 membered heterocyclyl and C3-8cycloalkylC1-8alkyl are unsubstituted or substituted with one or more substituents selected from halogen, cyano, cyanoC1-8alkyl, hydroxyl and hydroxylC1-8alkyl; R5ais independently selected from C1-8alkyl, haloC1-8alkyl, C3-12cycloalkyl and C3-8cycloalkylC1-8alkyl; at each occurrence, R5bis independently selected from –CH(R6)-NR7R8; R6is selected from hydrogen; R7is selected from hydrogen; R8is selected from C1-8alkyl, C3-12cycloalkyl and C3-8cycloalkylC1-8alkyl; R7and R8joined together with the nitrogen atom to which they are attached, form a 3-15 membered heterocyclyl; wherein 3-15 membered heterocyclyl is unsubstituted or substituted with one or more substituents selected from halogen and C1-8alkyl; ‘r’ is 0 or 1; ‘t’ is 0, 1 or 2; ‘m’ is 0, 1, 2 or 3; and ‘n’ is 1 or 2.
2. The compound of claim 1, wherein ring 3. The compound of any one of claims 14. The compound of any one of claims 1 to 3, wherein ‘r’ is 1.
5. The compound of any one of claims 1 to 4, wherein ring 26. The compound of any one of claims 1 to 5, wherein R cyano, or methyl.
7. The compound of any one of claims 1 to 6, wherein ‘t’ is 0, 1 or 2.
8. The compound of any one of claims 1 to 7, wherein X1is C or N.
9. The compound of any one of claims 1 to 8, wherein X2is C or N.
10. The compound of any one of claims 1 to 9, wherein R3is chloro, fluoro or cyclopropyl.
11. The compound of any one of claims 1 to 10, wherein ‘m’ is 0, 1, 2 or 3.13.1 to 12, wherein R5ais trifluoroethyl, methyl, cyclopropyl or cyclopropylmethyl.
16. The compound of claim 1, whereinR is trifluoroethyl, methyl, cyclopropyl or cyclopropylmethyl;‘t’ is 0, 1 or 2; and ‘n’ is 1.
17. The compound of claim 1, whereinR5ais trifluoroethyl, methyl, cyclopropyl or cyclopropylmethyl;‘t’ is 0, 1 or 2; and ‘n’ is 1.
18. The compound of claim 1, having represented by formula (IB):or a stereoisomer 19. The compound of claim 1, having represented by formula (IC):or a stereoisomer 20. The compound of claim 1, having represented by formula (ID):or a stereoisomer or a 21. A compound selected from:(S)-N-(4'-cyano-2'-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-3-yl)-5-((3- methylpiperidin-1-yl)methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3- carboxamide; N-(4'-cyano-2'-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-3-yl)-5- ((isobutylamino)methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3- carboxamide; 5-((Isobutylamino)methyl)-N-(2'-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]- 3-yl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3-carboxamide; N-(4'-Fluoro-2'-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-3-yl)-5- ((isobutylamino)methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3- carboxamide; (S)-N-(4'-Fluoro-2'-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-3-yl)-5-((3- methylpiperidin-1-yl)methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3- carboxamide; N-(4,4'-Difluoro-2'-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-3-yl)-5- ((isobutylamino)methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3- carboxamide; N-(5'-Fluoro-2'-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-3-yl)-5- ((isobutylamino)methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3- carboxamide; N-(4'-Cyano-4-fluoro-2'-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-3-yl)-5- ((isobutylamino)methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3- carboxamide; N-(4'-Fluoro-2'-(5-methyl-1H-1,2,3-triazol-1-yl)-[1,1'-biphenyl]-3-yl)-5- ((isobutylamino)methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3- carboxamide; N-(4'-Fluoro-2'-(5-methyl-1H-1,2,3-triazol-4-yl)-[1,1'-biphenyl]-3-yl)-5- ((isobutylamino)methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3- carboxamide; N-(4-(4-Fluoro-2-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)pyridin-2-yl)-5- ((isobutylamino)methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3- carboxamide;N-(4-Chloro-4'-fluoro-2'-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-3-yl)-5- ((isobutylamino)methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3- carboxamide; 1-(Cyclopropylmethyl)-N-(4'-fluoro-2'-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'- biphenyl]-3-yl)-5-((isobutylamino)methyl)-2-oxo-1,2-dihydropyridine-3- carboxamide; N-(4',5-Difluoro-2'-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-3-yl)-5- ((isobutylamino)methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3- carboxamide; N-(2,4'-Difluoro-2'-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-3-yl)-5- ((isobutylamino)methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3- carboxamide; 5-(((Cyclopropylmethyl)amino)methyl)-N-(4'-fluoro-2'-(4-methyl-4H-1,2,4- triazol-3-yl)-[1,1'-biphenyl]-3-yl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine- 3-carboxamide; N-(4'-Fluoro-2'-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-3-yl)-5-(((1- methylcyclobutyl)amino)methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine- 3-carboxamide; N-(4-(4-Fluoro-2-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)pyridin-2-yl)-5- ((isobutylamino)methyl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide; N-(4'-Chloro-2'-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-3-yl)-5- ((isobutylamino)methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3- carboxamide; 1-Cyclopropyl-N-(4'-fluoro-2'-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-3- yl)-5-((isobutylamino)methyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-(4',5'-Difluoro-2'-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-3-yl)-5- ((isobutylamino)methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3- carboxamide; N-(4'-Fluoro-2'-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-3-yl)-5- ((neopentylamino)methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3- carboxamide;N-(4'-Fluoro-2'-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-3-yl)-5- ((isopentylamino)methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3- carboxamide; 5-((4,4-Difluoro-3-methylpiperidin-1-yl)methyl)-N-(4'-fluoro-2'-(4-methyl-4H- 1,2,4-triazol-3-yl)-[1,1'-biphenyl]-3-yl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2- dihydropyridine-3-carboxamide; N-(4',5'-Difluoro-2'-(4-methyl-4H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-3-yl)-5-(((1- methylcyclobutyl)amino)methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihy dropyridine- 3-carboxamide; N-(6-Cyclopropyl-4-(4-fluoro-2-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)pyridin-2- yl)-5-((isobutylamino)methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3- carboxamide; N-(6-Cyclopropyl-4-(4-fluoro-2-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)pyridin-2- yl)-5-(((1-methylcyclobutyl)amino)methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2- dihydropyridine-3-carboxamide; N-(6-(4-Fluoro-2-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-2-methylimidazo[1,2- a]pyridin-8-yl)-5-((isobutylamino)methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2- dihydropyridine-3-carboxamide; N-(6-(4-Fluoro-2-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-2-methylimidazo[1,2- a]pyridin-8-yl)-5-((isobutylamino)methyl)-1-methyl-2-oxo-1,2-dihydropyridine-3- carboxamide; N-(6-(4-Fluoro-2-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)quinolin-8-yl)-5- ((isobutylamino)methyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3- carboxamide; 5-((Isobutylamino)methyl)-N-(3-(1-methyl-4-(4-methyl-4H-1,2,4-triazol-3-yl)-1H- pyrazol-3-yl)phenyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1,2-dihydropyridine-3- carboxamide; and (S)-N-(6-(4-Fluoro-2-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-1-methyl-1H- benzo[d]imidazol-4-yl)-5-((3-methylpiperidin-1-yl)methyl)-2-oxo-1-(2,2,2- trifluoroethyl)-1,2-dihydropyridine-3-carboxamide; or a pharmaceutically acceptable salt thereof.
22. A pharmaceutical composition comprising a compound of any one of claims 1 to 21 and a pharmaceutically acceptable excipient.
23. The pharmaceutical composition of claim 22, wherein the pharmaceutically acceptable excipient is a carrier, adjuvant, diluent or a vehicle.
24. A method of treating or preventing from a disease, disorder, or condition mediated by CBL-b in a subject comprising administering the subject in need thereof an effective amount of a compound of any one of claims 1 to 21.
25. The method of claim 24, wherein the disease, disorder, or condition is cancer.
Citation Information
Patent Citations
Heterocyclic compounds as immunomodulators
US20180016260A1
Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
US9012635B2
Urea, amide, and substituted heteroaryl compounds for cbl-b inhibition
WO2021021761A1
Cited By
Cbl-b inhibitors and methods of use thereof
US20260116868A1
Cbl-b inhibitors and methods of use thereof
WO2025076299A1
